WO2009079796A1 - Recombinant rsv antigens - Google Patents
Recombinant rsv antigens Download PDFInfo
- Publication number
- WO2009079796A1 WO2009079796A1 PCT/CA2008/002277 CA2008002277W WO2009079796A1 WO 2009079796 A1 WO2009079796 A1 WO 2009079796A1 CA 2008002277 W CA2008002277 W CA 2008002277W WO 2009079796 A1 WO2009079796 A1 WO 2009079796A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- rsv
- domain
- antigen
- rsv antigen
- Prior art date
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 279
- 102000036639 antigens Human genes 0.000 title claims abstract description 279
- 239000000427 antigen Substances 0.000 title claims abstract description 278
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 236
- 239000000203 mixture Substances 0.000 claims abstract description 171
- 230000002163 immunogen Effects 0.000 claims abstract description 111
- 238000000034 method Methods 0.000 claims abstract description 53
- 229960005486 vaccine Drugs 0.000 claims abstract description 35
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 150
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 129
- 229920001184 polypeptide Polymers 0.000 claims description 127
- 235000001014 amino acid Nutrition 0.000 claims description 121
- 150000001413 amino acids Chemical group 0.000 claims description 120
- 229940024606 amino acid Drugs 0.000 claims description 101
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 96
- 210000004027 cell Anatomy 0.000 claims description 93
- 150000007523 nucleic acids Chemical class 0.000 claims description 92
- 102000039446 nucleic acids Human genes 0.000 claims description 91
- 108020004707 nucleic acids Proteins 0.000 claims description 91
- 102000030782 GTP binding Human genes 0.000 claims description 89
- 108091000058 GTP-Binding Proteins 0.000 claims description 89
- 108090000623 proteins and genes Proteins 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 235000018102 proteins Nutrition 0.000 claims description 73
- 239000002671 adjuvant Substances 0.000 claims description 67
- 108091006027 G proteins Proteins 0.000 claims description 65
- 230000028993 immune response Effects 0.000 claims description 54
- 230000004044 response Effects 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 41
- 239000013598 vector Substances 0.000 claims description 36
- 102000040430 polynucleotide Human genes 0.000 claims description 35
- 108091033319 polynucleotide Proteins 0.000 claims description 35
- 239000002157 polynucleotide Substances 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 27
- 244000052769 pathogen Species 0.000 claims description 26
- 102000004961 Furin Human genes 0.000 claims description 25
- 108090001126 Furin Proteins 0.000 claims description 25
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 23
- 238000003776 cleavage reaction Methods 0.000 claims description 22
- 230000004048 modification Effects 0.000 claims description 22
- 238000012986 modification Methods 0.000 claims description 22
- 230000007017 scission Effects 0.000 claims description 22
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 18
- 230000004927 fusion Effects 0.000 claims description 17
- 238000005829 trimerization reaction Methods 0.000 claims description 17
- 230000002209 hydrophobic effect Effects 0.000 claims description 15
- 239000002243 precursor Substances 0.000 claims description 15
- 230000001681 protective effect Effects 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 14
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 239000013638 trimer Substances 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 241000238631 Hexapoda Species 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 10
- 229960000310 isoleucine Drugs 0.000 claims description 10
- 239000007764 o/w emulsion Substances 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000001575 pathological effect Effects 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 229940037003 alum Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 201000005702 Pertussis Diseases 0.000 claims description 3
- 206010043376 Tetanus Diseases 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 206010013023 diphtheria Diseases 0.000 claims description 3
- 229920002704 polyhistidine Polymers 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 230000006229 amino acid addition Effects 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000556 agonist Substances 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 102000002689 Toll-like receptor Human genes 0.000 description 25
- 108020000411 Toll-like receptor Proteins 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 24
- 239000012634 fragment Substances 0.000 description 23
- 230000001717 pathogenic effect Effects 0.000 description 21
- 230000000087 stabilizing effect Effects 0.000 description 20
- 230000011664 signaling Effects 0.000 description 19
- 239000012528 membrane Substances 0.000 description 16
- 235000004252 protein component Nutrition 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 150000007949 saponins Chemical class 0.000 description 15
- 238000007792 addition Methods 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 229930182490 saponin Natural products 0.000 description 14
- 235000017709 saponins Nutrition 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- -1 lysine Chemical class 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 10
- 230000003308 immunostimulating effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000002349 favourable effect Effects 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 101710116435 Outer membrane protein Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 6
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 6
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000002480 immunoprotective effect Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940031439 squalene Drugs 0.000 description 6
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- 108010075142 Protollin Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 229940087168 alpha tocopherol Drugs 0.000 description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229940107161 cholesterol Drugs 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000000569 multi-angle light scattering Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229960000984 tocofersolan Drugs 0.000 description 5
- 239000002076 α-tocopherol Substances 0.000 description 5
- 235000004835 α-tocopherol Nutrition 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000588653 Neisseria Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102000017033 Porins Human genes 0.000 description 4
- 108010013381 Porins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000000799 fusogenic effect Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010028921 Lipopeptides Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000256251 Spodoptera frugiperda Species 0.000 description 3
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
- 159000000013 aluminium salts Chemical class 0.000 description 3
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 102100033668 Cartilage matrix protein Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 241000711920 Human orthopneumovirus Species 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241001092142 Molina Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 241001454523 Quillaja saponaria Species 0.000 description 2
- 235000009001 Quillaja saponaria Nutrition 0.000 description 2
- 229940124679 RSV vaccine Drugs 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 229940124614 TLR 8 agonist Drugs 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229940001007 aluminium phosphate Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000013320 baculovirus expression vector system Methods 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical group [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 238000001825 field-flow fractionation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 102000005396 glutamine synthetase Human genes 0.000 description 2
- 108020002326 glutamine synthetase Proteins 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 229940124669 imidazoquinoline Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- QZRAABPTWGFNIU-UHFFFAOYSA-N 3-[dimethyl(octyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O QZRAABPTWGFNIU-UHFFFAOYSA-N 0.000 description 1
- 102100031765 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Human genes 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091027551 Cointegrate Proteins 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102100031096 Cubilin Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101000738180 Euglena gracilis Chaperonin CPN60, mitochondrial Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101000866618 Homo sapiens 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 238000003231 Lowry assay Methods 0.000 description 1
- 238000009013 Lowry's assay Methods 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940124615 TLR 7 agonist Drugs 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- GOWLTLODGKPXMN-MWJFIXGVSA-N [(3r)-1-[[(2r,3r,4r,5s,6r)-2-[[(2r,3s,4r,5r,6r)-3,4-dihydroxy-5-[[(3r)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-2-yl]methoxy]-4-hydroxy-6-(hydroxymethyl)-5-phosphonooxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] dodecanoate Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MWJFIXGVSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000000787 affinity precipitation Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010088716 attachment protein G Proteins 0.000 description 1
- 210000001224 bacterial fimbriae Anatomy 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000007496 glass forming Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical group C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108010003082 intrinsic factor-cobalamin receptor Proteins 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical group NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 101150091813 shfl gene Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This disclosure concerns the field of immunology. More particularly this disclosure relates to compositions and methods for eliciting an immune response specific for Respiratory Syncytial Virus (RSV).
- RSV Respiratory Syncytial Virus
- RSV Human Respiratory Syncytial Virus
- LRI lower respiratory tract infections
- the RSV disease spectrum includes a wide array of respiratory symptoms from rhinitis and otitis to pneumonia and bronchiolitis, the latter two diseases being associated with considerable morbidity and mortality.
- Humans are the only known reservoir for RSV.
- Spread of the virus from contaminated nasal secretions occurs via large respiratory droplets, so close contact with an infected individual or contaminated surface is required for transmission.
- RSV can persist for several hours on toys or other objects, which explains the high rate of nosocomial RSV infections, particularly in paediatric wards.
- RSV The global annual infection and mortality figures for RSV are estimated to be 64 million and 160,000 respectively. In the U.S. alone RSV is estimated to be responsible for 18,000 to 75,000 hospitalizations and 90 to 1900 deaths annually. In temperate climates, RSV is well documented as a cause of yearly winter epidemics of acute LRI, including bronchiolitis and pneumonia. In the USA, nearly all children have been infected with RSV by two years of age. The incidence rate of RSV-associated LRI in otherwise healthy children was calculated as 37 per 1000 child-year in the first two years of life (45 per 1000 child-year in infants less than 6 months old) and the risk of hospitalization as 6 per 1000 child-years ( per 1000 child-years in the first six months of life).
- This disclosure concerns recombinant respiratory syncytial virus (RSV) antigens. More specifically, this disclosure concerns antigens including a recombinant F protein that has been modified to stabilize the trimeric prefusion conformation.
- the disclosed recombinant antigens exhibit superior immunogenicity, and are particularly favorably employed as components of immunogenic compositions (e.g., vaccines) for protection against RSV infection and/or disease.
- immunogenic compositions e.g., vaccines
- nucleic acids that encode the recombinant antigens, immunogenic compositions containing the antigens, and methods for producing and using the antigens.
- FIG. IA is a schematic illustration highlighting structural features of the RSV F protein.
- FIG. IB is a schematic illustration of exemplary RSV Prefusion F (PreF) antigens.
- FIG. 2 is a line graph illustrating representative results of asymmetrical field flow fractionation (AFF-MALS) analysis of PreF.
- AFF-MALS asymmetrical field flow fractionation
- FIG. 3 is a bar graph showing neutralization inhibition of human serum by PreF antigen.
- FIGS. 4A and B are bar graphs showing serum IgG titers elicited in mice in response to PreF antigen.
- FIGS. 5 A and B are bar graphs illustrating titers of neutralizing antibodies specific for RSV elicited by PreF antigen.
- FIGS. 6A and B are graphs indicating protection against challenge provided by the RSV PreF antigen in mice.
- FIG. 7 is a graph evaluating BAL leukocytes following immunization and challenge.
- the present disclosure concerns recombinant respiratory syncytial virus (RSV) antigens that solve problems encountered with RSV antigens previously used in vaccines, and improve the immunological as well as manufacturing properties of the antigen.
- RSV antigens disclosed herein involve a Fusion (F) protein analog that include a soluble F protein polypeptide, which has been modified to stabilize the prefusion conformation of the F protein, that is, the conformation of the mature assembled F protein prior to fusion with the host cell membrane.
- F Fusion
- PreF antigens disclosed herein are predicated on the unforeseen discovery that soluble F protein analogs that have been modified by the incorporation of a heterologous trimerization domain exhibit improved immunogenic characteristics, and are safe and highly protective when administered to a subject in vivo.
- FIG. IA Details of the structure of the RSV F protein are provided herein with reference to terminology and designations widely accepted in the art, and illustrated schematically in FIG. IA.
- FIG. IB A schematic illustration of exemplary PreF antigens is provided in FIG. IB.
- any RSV F protein can be modified to stabilize the prefusion conformation according to the teachings provided herein. Therefore, to facilitate understanding of the principles guiding production of PreF antigens, individual structural components will be indicated with reference to an exemplary F protein, the polynucleotide and amino acid sequence of which are provided in SEQ ID NOs: 1 and 2, respectively.
- G protein antigens are described in reference to an exemplary G protein, the polynucleotide and amino acid sequences of which are provided in SEQ ID NOs: 3 and 4, respectively.
- the term FO refers to a full-length translated F protein precursor.
- the FO polypeptide can be subdivided into an F2 domain and an Fl domain separated by an intervening peptide, designated pep27.
- pep27 an intervening peptide
- the FO polypeptide undergoes proteolytic cleavage at two furin sites situated between F2 and Fl and flanking pep27.
- an F2 domain includes at least a portion, and as much as all, of amino acids 1-109
- a soluble portion of an Fl domain includes at least a portion, and up to all, of amino acids 137-526 of the F protein.
- the prefusion F (or "PreF") antigen is a soluble (that is, not membrane bound) F protein analog that includes at least one modification that stabilizes the prefusion conformation of the F protein, such that the RSV antigen retains at least one immunodominant epitope of the prefusion conformation of the F protein.
- the soluble F protein polypeptide includes an F2 domain and an Fl domain of the RSV F protein (but does not include a transmembrane domain of the RSV F protein).
- the F2 domain includes amino acids 26-105 and the Fl domain includes amino acids 137-516 of an F protein.
- smaller portions can also be used, so long as the three-dimensional conformation of the stabilized PreF antigen is maintained.
- polypeptides that include additional structural components e.g., fusion polypeptides
- polypeptides that include additional structural components can also be used in place of the exemplary F2 and Fl domains, so long as the additional components do not disrupt the three-dimensional conformation, or otherwise adversely impact stability, production or processing, or decrease immunogenicity of the antigen.
- the F2 and Fl domains are positioned in an N-terminal to C-terminal orientation designed to replicate folding and assembly of the F protein analog into the mature prefusion conformation.
- the F2 domain can be preceded by a secretory signal peptide, such as a native F protein signal peptide or a heterologous signal peptide chosen to enhance production and secretion in the host cells in which the recombinant PreF antigen is to be expressed.
- a secretory signal peptide such as a native F protein signal peptide or a heterologous signal peptide chosen to enhance production and secretion in the host cells in which the recombinant PreF antigen is to be expressed.
- the PreF antigens are stabilized (in the trimeric prefusion conformation) by introducing one or more modifications, such as the addition, deletion or substitution, or one or more amino acids.
- One such stabilizing modification is the addition of an amino acid sequence comprising a heterologous stabilizing domain.
- the heterologous stabilizing domain is a protein multimerization domain.
- a protein multimerization domain is a particularly favorable example of such a protein multimerization domain.
- a coiled-coil domain such as an isoleucine zipper domain that promotes trimerization of multiple polypeptides having such a domain.
- An exemplary isoleucine zipper domain is depicted in SEQ ID NO:11.
- the heterologous stabilizing domain is positioned C-terminal to the Fl domain.
- the multimerization domain is connected to the Fl domain via a short amino acid linker sequence, such as the sequence GG.
- the linker can also be a longer linker (for example, including the sequence GG, such as the amino acid sequence: GGSGGSGGS; SEQ ID NO: 14).
- Numerous conformationally neutral linkers are known in the art that can be used in this context without disrupting the conformation of the PreF antigen.
- Another stabilizing modification is the elimination of a furin recognition and cleavage site that is located between the F2 and Fl domains in the native FO protein.
- One or both furin recognition sites, located at positions 105-109 and at positions 133-136 can be eliminated by deleting or substituting one or more amino acid of the furin recognition sites, such that the protease is incapable of cleaving the PreF polypeptide into its constituent domains.
- the intervening pep27 peptide can also be removed or substituted, e.g., by a linker peptide.
- a non-furin cleavage site e.g., a metalloproteinase site at positions 112-113
- a non-furin cleavage site e.g., a metalloproteinase site at positions 112-113
- a stabilizing mutation is the addition or substitution of a hydrophilic amino acid into a hydrophobic domain of the F protein.
- a charged amino acid such as lysine
- a neutral residue such as leucine
- a hydrophilic amino acid can be added to, or substituted for, a hydrophobic or neutral amino acid within the HRB coiled-coil domain of the F protein extracellular domain.
- a charged amino acid residue such as lysine, can be substituted for the leucine present at position 512 of the F protein.
- a hydrophilic amino acid can be added to, or substituted for, a hydrophobic or neutral amino acid within the HRA domain of the F protein.
- one or more charged amino acids such as lysine
- hydrophilic amino acids can be added or substituted in both the HRA and HRB domains.
- one or more hydrophobic residues can be deleted, so long as the overall conformation of the PreF antigen is not adversely impacted.
- the stabilizing modifications can be used individually and/or in combination with any of the other stabilizing modifications disclosed herein to produce a PreF antigen.
- the PreF protein comprising a polypeptide comprising an F2 domain and an Fl domain with no intervening furin cleavage site between the F2 domain and the Fl domain, and with a heterologous stabilizing domain (e.g., trimerization domain) positioned C-terminal to the Fl domain.
- the PreF antigen also includes one or more addition and/or substitution of a hydrophilic residue into a hydrophobic HRA and/or HRB domain.
- the PreF antigen has a modification of at least one non-furin cleavage site, such as a metalloproteinase site.
- a PreF antigen can optionally include an additional polypeptide component that includes at least an immunogenic portion of the RSV G protein. That is, in certain embodiments, the PreF antigen is a chimeric protein that includes both an F protein and a G protein component.
- the F protein component can be any of the PreF antigens described above, and the G protein component is selected to be an immunologically active portion of the RSV G protein (up to and/or including a full-length G protein).
- the G protein polypeptide includes amino acids 149-229 of a G protein (where the amino acid positions are designated with reference to the G protein sequence represented in SEQ ID NO:4).
- a smaller portion or fragment of the G protein can be used, so long as the selected portion retains the dominant immunologic features of the larger G protein fragment.
- the selected fragment retains the immunologically dominant epitope between about amino acid positions 184-198 (e.g., amino acids 180-200), and be sufficiently long to fold and assemble into a stable conformation that exhibits the immunodominant epitope.
- Longer fragments can also be used, e.g., from about amino acid 128 to about amino acid 229, up to the full-length G protein. So long as the selected fragment folds into a stable conformation in the context of the chimeric protein, and does not interfere with production, processing or stability when produced recombinantly in host cells.
- the G protein component is connected to the F protein component via a short amino acid linker sequence, such as the sequence GG.
- the linker can also be a longer linker (such as the amino acid sequence: GGSGGSGGS: SEQ ID NO:14).
- Numerous conformationally neutral linkers are known in the art that can be used in this context without disrupting the conformation of the PreF antigen.
- the G protein component can include one or more amino acid substitutions that reduce or prevent enhanced viral disease in an animal model of RSV disease. That is, the G protein can include an amino acid substitution, such that when an immunogenic composition including the PreF-G chimeric antigen is administered to a subject selected from an accepted animal model (e.g., mouse model of RSV), the subject exhibits reduced or no symptoms of vaccine enhanced viral disease (e.g., eosinophilia, neutrophilia), as compared to a control animal receiving a vaccine including that contains an unmodified G protein.
- an immunogenic composition including the PreF-G chimeric antigen is administered to a subject selected from an accepted animal model (e.g., mouse model of RSV), the subject exhibits reduced or no symptoms of vaccine enhanced viral disease (e.g., eosinophilia, neutrophilia), as compared to a control animal receiving a vaccine including that contains an unmodified G protein.
- vaccine enhanced viral disease e.g., eosinophili
- the reduction and/or prevention of vaccine enhanced viral disease can be apparent when the immunogenic compositions are administered in the absence of adjuvant (but not, for example, when the antigens are administered in the presence of a strong ThI inducing adjuvant).
- the amino acid substitution can reduce or prevent vaccine enhanced viral disease when administered to a human subject.
- An example of a suitable amino acid substitution is the replacement of asparagine at position 191 by an alanine (Asn ⁇ Ala at amino acid 191: Nl 91A).
- any PreF antigen described above can include an additional sequence that serves as an aid to purification.
- an additional sequence that serves as an aid to purification.
- a polyhistidine tag Such a tag can be removed from the final product if desired.
- the PreF antigens When expressed, the PreF antigens undergo intramolecular folding and assemble into mature protein that includes a multimer of polypeptides.
- the preF antigen polypeptides assemble into a trimer that resembles the prefusion conformation of the mature, processed, RSV F protein.
- any of the PreF antigens (including PreF-G antigens) disclosed herein can be favorably used in immunogenic compositions for the purpose of eliciting a protective immune response against RSV.
- immunogenic compositions typically include a pharmaceutically acceptable carrier and/or excipient, such as a buffer.
- the immunogenic composition typically also includes an adjuvant.
- the compositions favorably include an adjuvant that predominantly elicits a ThI immune response (a ThI biasing adjuvant).
- the adjuvant is selected to be suitable for administration to the target population to which the composition is to be administered.
- the adjuvant is selected to be suitable for administration, e.g., to neonates or to the elderly.
- compositions described herein are favorably employed as vaccines for the reduction or prevention of infection with RSV, without inducing a pathological response (such as vaccine enhanced viral disease) following administration or exposure to RSV.
- the immunogenic composition includes a PreF antigen (such as the exemplary embodiment illustrated by SEQ ID NO:6) and a second polypeptide that includes a G protein component.
- the G protein component typically includes at least amino acids 149-229 of a G protein. Although smaller portions of the G protein can be used, such fragments should include, at a minimum, the immunological dominant epitope of amino acids 184-198.
- the G protein can include a larger portion of the G protein, such as amino acids 128-229 or 130-230, optionally as an element of a larger protein, such as a full-length G protein, or a chimeric polypeptide.
- the immunogenic composition includes a PreF antigen that is a chimeric protein that also includes a G protein component (such as the exemplary embodiments illustrated by SEQ ID NOs: 8 and 10).
- the G protein component of such a chimeric PreF (or PreF-G) antigen typically includes at least amino acids 149-229 of a G protein.
- smaller or larger fragments (such as amino acids 129-229 or 130-230) of the G protein can also be used, so long as the immunodominant epitopes are retained, and conformation of the PreF-G antigen is not adversely impacted.
- the immunogenic compositions can also include at least one additional antigen of a pathogenic organism other than RSV.
- the pathogenic organism is a virus other than RSV, such as Parainfluenza virus (PIV), measles, hepatitis B, poliovirus, or influenza virus.
- the pathogenic organism can be a bacterium, such as diphtheria, tetanus, pertussis, Haemophilus influenzae, and Pneumococcus.
- nucleic acids that encode any of the PreF antigens are also a feature of this disclosure.
- the polynucleotide sequence of the nucleic acid that encodes the PreF antigen of the nucleic acid is optimized for expression in a selected host (such as CHO cells, other mammalian cells, or insect cells).
- a selected host such as CHO cells, other mammalian cells, or insect cells.
- vectors, including expression vectors including prokaryotic and eukaryotic expression vectors
- host cells including such nucleic acids, and vectors, are a feature of this disclosure.
- nucleic acids can also be used in the context of immunogenic compositions for administration to a subject to elicit an immune response specific for RSV.
- the PreF antigens are favorably used for the prevention and/or treatment of RSV infection.
- another aspect of this disclosure concerns a method for eliciting an immune response against RSV. The method involves administering an immunologically effective amount of a composition containing a PreF antigen to a subject (such as a human or animal subject). Administration of an immunologically effective amount of the composition elicits an immune response specific for epitopes present on the PreF antigen.
- Such an immune response can include B cell responses (e.g., the production of neutralizing antibodies) and/or T cell responses (e.g., the production of cytokines).
- the immune response elicited by the PreF antigen includes elements that are specific for at least one conformational epitope present on the prefusion conformation of the RSV F protein.
- the PreF antigens and compositions can be administered to a subject without enhancing viral disease following contact with RSV.
- the PreF antigens disclosed herein and suitably formulated immunogenic compositions elicit a ThI biased immune response that reduces or prevents infection with a RSV and/or reduces or prevents a pathological response following infection with a RSV.
- the immunogenic compositions can be administered via a variety of routes, including routes, such as intranasal, that directly place the PreF antigen in contact with the mucosa of the upper respiratory tract.
- routes such as intranasal, that directly place the PreF antigen in contact with the mucosa of the upper respiratory tract.
- more traditional administration routes can be employed, such an intramuscular route of administration.
- any of the disclosed RSV antigens (or nucleic acids) in the preparation of a medicament for treating RSV infection is also contemplated. Accordingly, this disclosure provides the disclosed recombinant RSV antigens or the immunogenic compositions for use in medicine, as well as the use thereof for the prevention or treatment of RSV-associated diseases.
- Respiratory syncytial virus is a pathogenic virus of the family Paramyxoviridae, subfamily Pneumovirinae, genus Pneumovirus.
- the genome of RSV is a negative-sense RNA molecule, which encodes 11 proteins. Tight association of the RNA genome with the viral N protein forms a nucleocapsid wrapped inside the viral envelope.
- Two groups of human RSV strains have been described, the A and B groups, based on differences in the antigenicity of the G glycoprotein. Numerous strains of RSV have been isolated to date.
- Exemplary strains indicated by GenBank and/or EMBL Accession number can be found in WO2008114149, which is incorporated herein by reference for the purpose of disclosing the nucleic acid and polypeptide sequences of RSV F and G proteins suitable for use in PreF antigens (including chimeric PreF-G antigens), and in combinations with PreF antigens. Additional strains of RSV are likely to be isolated, and are encompassed within the genus of RSV. Similarly, the genus of RSV encompasses variants arising from naturally occurring (e.g., previously or subsequently identified strains) by genetic drift, or artificial synthesis and/or recombination.
- F protein or "Fusion protein” or “F protein polypeptide” or Fusion protein polypeptide” refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Fusion protein polypeptide.
- G protein or “G protein polypeptide” refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Attachment protein polypeptide.
- Numerous RSV Fusion and Attachment proteins have been described and are known to those of skill in the art.
- WO2008114149 sets out exemplary F and G protein variants (for example, naturally occurring variants) publicly available as of the filing date of this disclosure.
- a "variant" when referring to a nucleic acid or a polypeptide is a nucleic acid or a polypeptide that differs from a reference nucleic acid or polypeptide.
- the difference(s) between the variant and the reference nucleic acid or polypeptide constitute a proportionally small number of differences as compared to the referent.
- a "domain" of a polypeptide or protein is a structurally defined element within the polypeptide or protein.
- a trimerization domain is an amino acid sequence within a polypeptide that promotes assembly of the polypeptide into trimers.
- a trimerization domain can promote assembly into trimers via associations with other trimerization domains (of additional polypeptides with the same or a different amino acid sequence).
- the term is also used to refer to a polynucleotide that encodes such a peptide or polypeptide.
- nucleic acid refers to an an element, such as a protein, polypeptide or nucleic acid, that is present in the same state as it is in nature. That is, the element has not been modified artificially. It will be understood, that in the context of this disclosure, there are numerous native/naturally occurring variants of RSV proteins or polypeptides, e.g., obtained from different naturally occurring strains or isolates of RSV.
- polypeptide refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds.
- polypeptide or protein as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins.
- polypeptide is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced.
- fragment in reference to a polypeptide, refers to a portion (that is, a subsequence) of a polypeptide.
- immunogenic fragment refers to all fragments of a polypeptide that retain at least one predominant immunogenic epitope of the full-length reference protein or polypeptide.
- Orientation within a polypeptide is generally recited in an N-terminal to C-terminal direction, defined by the orientation of the amino and carboxy moieties of individual amino acids. Polypeptides are translated from the N or amino-terminus towards the C or carboxy-terminus.
- a "signal peptide” is a short amino acid sequence (e.g., approximately 18-25 amino acids in length) that direct newly synthesized secretory or membrane proteins to and through membranes, e.g., of the endoplasmic reticulum. Signal peptides are frequently but not universally located at the N-terminus of a polypeptide, and are frequently cleaved off by signal peptidases after the protein has crossed the membrane. Signal sequences typically contain three common structural features: an N-terminal polar basic region (n-region), a hydrophobic core, and a hydrophilic c-region).
- polynucleotide and “nucleic acid sequence” refer to a polymeric form of nucleotides at least 10 bases in length. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single and double forms of DNA.
- isolated polynucleotide is meant a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. In one embodiment, a polynucleotide encodes a polypeptide.
- the 5' and 3' direction of a nucleic acid is defined by reference to the connectivity of individual nucleotide units, and designated in accordance with the carbon positions of the deoxyribose (or ribose) sugar ring.
- the informational (coding) content of a polynucleotide sequence is read in a 5' to 3' direction.
- a "recombinant" nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.
- a "recombinant” protein is one that is encoded by a heterologous (e.g., recombinant) nucleic acid, which has been introduced into a host cell, such as a bacterial or eukaryotic cell.
- the nucleic acid can be introduced, on an expression vector having signals capable of expressing the protein encoded by the introduced nucleic acid or the nucleic acid can be integrated into the host cell chromosome.
- heterologous with respect to a a nucleic acid, a polypeptide or another cellular component, indicates that the component occurs where it is not normally found in nature and/or that it originates from a different source or species.
- purification refers to the process of removing components from a composition, the presence of which is not desired. Purification is a relative term, and does not require that all traces of the undesirable component be removed from the composition. In the context of vaccine production, purification includes such processes as centrifugation, dialization, ion-exchange chromatography, and size-exclusion chromatography, affinity- purification or precipitation. Thus, the term “purified” does not require absolute purity; rather, it is intended as a relative term.
- a purified nucleic acid preparation is one in which the specified protein is more enriched than the nucleic acid is in its generative environment, for instance within a cell or in a biochemical reaction chamber.
- a preparation of substantially pure nucleic acid or protein can be purified such that the desired nucleic acid represents at least 50% of the total nucleic acid content of the preparation.
- a substantially pure nucleic acid will represent at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95% or more of the total nucleic acid or protein content of the preparation.
- An "isolated" biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, such as, other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles.
- Nucleic acids and proteins that have been "isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins.
- an "antigen” is a compound, composition, or substance that can stimulate the production of antibodies and/or a T cell response in an animal, including compositions that are injected, absorbed or otherwise introduced into an animal.
- the term “antigen” includes all related antigenic epitopes.
- the term “epitope” or “antigenic determinant” refers to a site on an antigen to which B and/or T cells respond.
- the "dominant antigenic epitopes" or “dominant epitope” are those epitopes to which a functionally significant host immune response, e.g., an antibody response or a T-cell response, is made.
- the dominant antigenic epitopes are those antigenic moieties that when recognized by the host immune system result in protection from disease caused by the pathogen.
- T-cell epitope refers to an epitope that when bound to an appropriate MHC molecule is specifically bound by a T cell (via a T cell receptor).
- B-cell epitope is an epitope that is specifically bound by an antibody (or B cell receptor molecule).
- An "adjuvant” is an agent that enhances the production of an immune response in a non-specific manner.
- Common adjuvants include suspensions of minerals (alum, aluminum hydroxide, aluminum phosphate) onto which antigen is adsorbed; emulsions, including water-in-oil, and oil-in- water (and variants therof, including double emulsions and reversible emulsions), liposaccharides, lipopolysaccharides, immunostimulatory nucleic acids (such as CpG oligonucleotides), liposomes, Toll-like Receptor agonists (particularly, TLR2, TLR4, TLR7/8 and TLR9 agonists), and various combinations of such components.
- an "immunogenic composition” is a composition of matter suitable for administration to a human or animal subject (e.g., in an experimental setting) that is capable of eliciting a specific immune response, e.g., against a pathogen, such as RSV.
- an immunogenic composition includes one or more antigens (for example, polypeptide antigens) or antigenic epitopes.
- An immunogenic composition can also include one or more additional components capable of eliciting or enhancing an immune response, such as an excipient, carrier, and/or adjuvant.
- immunogenic compositions are administered to elicit an immune response that protects the subject against symptoms or conditions induced by a pathogen.
- immunogenic composition will be understood to encompass compositions that are intended for administration to a subject or population of subjects for the purpose of eliciting a protective or palliative immune response against RSV (that is, vaccine compositions or vaccines).
- An "immune response” is a response of a cell of the immune system, such as a B cell, T cell, or monocyte, to a stimulus.
- An immune response can be a B cell response, which results in the production of specific antibodies, such as antigen specific neutralizing antibodies.
- An immune response can also be a T cell response, such as a CD4+ response or a CD8+ response. In some cases, the response is specific for a particular antigen (that is, an "antigen-specific response").
- the antigen- specific response is a "pathogen-specific response.”
- a "protective immune response” is an immune response that inhibits a detrimental function or activity of a pathogen, reduces infection by a pathogen, or decreases symptoms (including death) that result from infection by the pathogen.
- a protective immune response can be measured, for example, by the inhibition of viral replication or plaque formation in a plaque reduction assay or ELISA-neutralization assay, or by measuring resistance to pathogen challenge in vivo.
- a “ThI” biased immune response is characterized by the presence of CD4+ T helper cells that produce IL-2 and IFN - ⁇ , and thus, by the secretion or presence of IL-2 and IFN- ⁇ .
- a “Th2" biased immune response is characterized by a preponderance of CD4+ helper cells that produce IL-4, IL-5, and IL- 13.
- an "immunologically effective amount” is a quantity of a composition (typically, an immunogenic composition) used to elicit an immune response in a subject to the composition or to an antigen in the composition.
- a composition typically, an immunogenic composition
- the desired result is the production of an antigen (e.g., pathogen)-specific immune response that is capable of or contributes to protecting the subject against the pathogen.
- an antigen e.g., pathogen
- the term immunologically effective amount encompasses a fractional dose that contributes in combination with previous or subsequent administrations to attaining a protective immune response.
- compositions and formulations suitable for pharmaceutical delivery of therapeutic and/or prophylactic compositions, including immunogenic compositions.
- modulate in reference to a response, such as an immune response, means to alter or vary the onset, magnitude, duration or characteristics of the response.
- An agent that modulates an immune response alters at least one of the onset, magnitude, duration or characteristics of an immune response following its administration, or that alters at least one of the onset, magnitude, duration or characteristic as compared to a reference agent.
- reduces is a relative term, such that an agent reduces a response or condition if the response or condition is quantitatively diminished following administration of the agent, or if it is diminished following administration of the agent, as compared to a reference agent.
- prevents does not necessarily mean that an agent completely eliminates the response or condition, so long as at least one characteristic of the response or condition is eliminated.
- an immunogenic composition that reduces or prevents an infection or a response can, but does not necessarily completely eliminate such an infection or response, so long as the infection or response is measurably diminished, for example, by at least about 50%, such as by at least about 70%, or about 80%, or even by about 90% of (that is to 10% or less than) the infection or response in the absence of the agent, or in comparison to a reference agent.
- a "subject" is a living multi-cellular vertebrate organism.
- the subject can be an experimental subject, such as a non-human animal, e.g., a mouse, a cotton rat, or a non-human primate.
- the subject can be a human subject.
- the RSV F protein is expressed as a single polypeptide precursor 574 amino acids in length, designated FO.
- FO oligomerizes in the endoplasmic reticulum and is proteolytically processed by a furin protease at two conserved furin consensus sequences (furin cleavage sites), RARR 109 (SEQ ID NO: 15) and RKRR 136 (SEQ ID NO: 16) to generate an oligomer consisting of two disulfide-linked fragments. The smaller of these fragments is termed F2 and originates from the N-terminal portion of the FO precursor.
- F 0 , F 1 and F 2 are commonly designated F 0 , F 1 and F 2 in the scientific literature.
- the larger, C-terminal Fl fragment anchors the F protein in the membrane via a sequence of hydrophobic amino acids, which are adjacent to a 24 amino acid cytoplasmic tail.
- Three F2-F1 dimers associate to form a mature F protein, which adopts a metastable prefusogenic (“prefusion") conformation that is triggered to undergo a conformational change upon contact with a target cell membrane.
- prefusion metastable prefusogenic
- This conformational change exposes a hydrophobic sequence, know as the fusion peptide, which associates with the host cell membrane and promotes fusion of the membrane of the virus, or an infected cell, with the target cell membrane.
- the Fl fragment contains at least two heptad repeat domains, designated HRA and HRB, and situated in proximity to the fusion peptide and transmembrane anchor domains, respectively.
- HRA and HRB heptad repeat domains
- the F2-F1 dimer forms a globular head and stalk structure, in which the HRA domains are in a segmented (extended) conformation in the globular head.
- the HRB domains form a three-stranded coiled coil stalk extending from the head region.
- the HRA domains collapse and are brought into proximity to the HRB domains to form an anti-parallel six helix bundle.
- the fusion peptide and transmembrane domains are juxtaposed to facilitate membrane fusion.
- prefusion and postfusion conformations can be monitored without resort to crystallography.
- electron micrography can be used to distinguish between the prefusion and postfusion (alternatively designated prefusogenic and fusogenic) conformations, as demonstrated by Calder et al, Virology, 271:122-131 (2000) and Morton et al, Virology, 311 :275-288, which are incorporated herein by reference for the purpose of their technological teachings.
- the prefusion conformation can also be distinguished from the fusogenic (postfusion) conformation by liposome association assays as described by Connolly et al, Proc. Natl.
- prefusion and fusogenic conformations can be distinguished using antibodies (e.g., monoclonal antibodies) that specifically recognize conformation epitopes present on one or the other of the prefusion or fusogenic form of the RSV F protein, but not on the other form.
- antibodies e.g., monoclonal antibodies
- conformation epitopes can be due to preferential exposure of an antigenic determinant on the surface of the molecule.
- conformational epitopes can arise from the juxtaposition of amino acids that are non-contiguous in the linear polypeptide.
- the PreF antigens disclosed herein are designed to stabilize and maintain the prefusion conformation of the RSV F protein, such that in a population of expressed protein, a substantial portion of the population of expressed protein is in the prefusogenic (prefusion) conformation (e.g., as predicted by structural and/or thermodynamic modeling or as assessed by one or more of the methods disclosed above).
- Stabilizing modifications are introduced into a native (or synthetic) F protein, such as the exemplary F protein of SEQ ID NO:2, such that the major immunogenic epitopes of the prefusion conformation of the F protein are maintained following introduction of the PreF antigen into a cellular or extracellular environment (for example, in vivo, e.g., following administration to a subject).
- a heterologous stabilizing domain can be placed at the C-terminal end of the construct in order to replace the membrane anchoring domain of the FO polypeptide.
- This stabilizing domain is predicted to compensate for the HRB instability, helping to stabilize the -prefusion conformer.
- the heterologous stabilizing domain is a protein multimerization domain.
- a protein multimerization domain is a trimerization domain.
- trimerization domains fold into a coiled-coil that promotes assembly into trimers of multiple polypeptides having such coiled-coil domains.
- trimerization domain is an isoleucine zipper.
- An exemplary isoleucine zipper domain is the engineered yeast GCN4 isoleucine variant described by Harbury et al. Science 262:1401-1407 (1993).
- the sequence of one suitable isoleucine zipper domain is represented by SEQ ID NO:11, although variants of this sequence that retain the ability to form a coiled-coil stabilizing domain are equally suitable.
- Alternative stabilizing coiled coil trimerization domains include: TRAF2 (GENBANK® Accession No. Q12933 [gi:23503103]; amino acids 299- 348); Thrombospondin 1 (Accession No. PO7996 [gi:135717]; amino acids 291-314); Matrilin-4 (Accession No.
- At least 50% of a recombinant PreF polypeptide having a trimerization domain will assemble into a trimer (e.g., as assessed by AFF-MALS).
- a trimer e.g., as assessed by AFF-MALS.
- the leucine residue located at position 512 (relative to the native FO protein) of the PreF can be substituted by a lysine (L482K of the exemplary PreF antigen polypeptide of SEQ ID NO:6). This substitution improves the coiled coil hydrophobic residue periodicity. Similarly, a lysine can be added following the amino acid at position 105.
- pep27 can be removed. Analysis of a structural model of the RSV F protein in the prefusion state suggests that pep27 creates a large unconstrained loop between Fl and F2. This loop does not contribute to stabilization of the prefusion state, and is removed following cleavage of the native protein by furin.
- one or both furin cleavage motifs can be deleted.
- the fusion peptide is not cleaved from F2, preventing release from the globular head of the prefusion conformer and accessibility to nearby membranes.
- Interaction between the fusion peptide and the membrane interface is predicted to be a major issue in the prefusion state instability.
- interaction between the fusion peptide and the target membrane results in the exposure of the fusion peptide from within the globular head structure, enhancing instability of the prefusion state and folding into post-fusion conformer.
- This conformation change enables the process of membrane fusion. Removal of one or both of the furin cleavage sites is predicted to prevent membrane accessibility to the N-terminal part of the fusion peptide, stabilizing the prefusion state.
- At least one non-furin cleavage site can also be removed, for example by substitution of one or more amino acids.
- the PreF antigen can be cleaved in the vicinity of amino acids 110-118 (for example, with cleavage occurring between amino acids 112 and 113 of the PreF antigen; between a leucine at position 142 and glycine at position 143 of the reference F protein polypeptide of SEQ ID NO:2). Accordingly, modification of one or more amino acids within this region can reduce cleavage of the PreF antigen.
- the leucine at position 112 can be substituted with a different amino acid, such as isoleucine or tryptophan.
- the glycine at position 113 can be substituted by a serine or alanine.
- the native F protein polypeptide can be selected from any F protein of an RSV A or RSV B strain, or from variants thereof (as defined above).
- the F protein polypeptide is the F protein represented by SEQ ID NO:2.
- SEQ ID NO:2 amino acid residue positions, regardless of strain, are given with respect to (that is, the amino acid residue position corresponds to) the amino acid position of the exemplary F protein.
- Comparable amino acid positions of any other RSV A or B strain can be determined easily by those of ordinary skill in the art by aligning the amino acid sequences of the selected RSV strain with that of the exemplary sequence using readily available and well-known alignment algorithms (such as BLAST, e.g., using default parameters).
- F protein polypeptides from different RSV strains are disclosed in WO2008114149 (which is incorporated herein by reference for the purpose of providing additional examples of RSV F and G protein sequences). Additional variants can arise through genetic drift, or can be produced artificially using site directed or random mutagenesis, or by recombination of two or more preexisting variants. Such additional variants are also suitable in the context of the PreF (and PreF-G) antigens disclosed herein. [076] In selecting F2 and Fl domains of the F protein, one of skill in the art will recognize that it is not strictly necessary to include the entire F2 and/or Fl domain.
- the F2 domain typically includes a portion of the F2 domain that facilitates assembly and stability of the polypeptide.
- the F2 domain includes amino acids 26-105.
- variants having minor modifications in length are also possible.
- At least a subsequence (or fragment) of the Fl domain is selected and designed to maintain a stable conformation that includes immunodominant epitopes of the F protein.
- an Fl domain polypeptide comprises at least about amino acids 262-436 of an RSV F protein polypeptide.
- the Fl domain comprises amino acids 137 to 516 of a native F protein polypeptide.
- sequences e.g., variants, subsequences, and the like.
- additional T cell epitopes can be identified using anchor motifs or other methods, such as neural net or polynomial determinations, known in the art, see, e.g., RANKPEP (available on the world wide web at: mif.dfci.harvard.edu/Tools/rankpep.html); ProPredI (available on the world wide web at: imtech.res.in/raghava/propredl/index.html); Bimas (available on the world wide web at: www-bimas.dcrt.nih.gov/molbi/hla bind/index.html); and SYFPEITH (available on the world wide web at: syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm).
- RANKPEP available on the world wide web at: mif.dfci.harvard.edu/Tools/rankpep.html
- ProPredI available
- algorithms are used to determine the "binding threshold" of peptides, and to select those with scores that give them a high probability of MHC or antibody binding at a certain affinity.
- the algorithms are based either on the effects on MHC binding of a particular amino acid at a particular position, the effects on antibody binding of a particular amino acid at a particular position, or the effects on binding of a particular substitution in a motif-containing peptide.
- a "conserved residue” is one which appears in a significantly higher frequency than would be expected by random distribution at a particular position in a peptide.
- Anchor residues are conserved residues that provide a contact point with the MHC molecule. T cell epitopes identified by such predictive methods can be confirmed by measuring their binding to a specific MHC protein and by their ability to stimulate T cells when presented in the context of the MHC protein.
- the PreF antigens include a signal peptide corresponding to the expression system, for example, a mammalian or viral signal peptide, such as an RSV FO native signal sequence (e.g., amino acids 1-25 of SEQ ID NO:2 or amino acids 1-25 of SEQ ID NO:6).
- the signal peptide is selected to be compatible with the cells selected for recombinant expression.
- a signal peptide such as a baculovirus signal peptide, or the melittin signal peptide, can be substituted for expression, in insect cells. Suitable plant signal peptides are known in the art, if a plant expression system is preferred.
- any of the preceding antigens can include an additional sequence or tag, such as a His-tag to facilitate purification.
- the PreF antigen can include additional immunogenic components.
- the PreF antigen includes an RSV G protein antigenic component.
- Exemplary chimeric proteins having a PreF and G component include the following PreF Vl (represented by SEQ ID NOs:7 and 8) and PreF_V2 (represented by SEQ ID NOs:9 and 10).
- an antigenic portion of the G protein (e.g. , a truncated G protein, such as amino acid residues 149-229) is added at the C-terminal end of the construct.
- the G protein component is joined to the F protein component via a flexible linker sequence.
- the G protein is joined to the PreF component by a -GGSGGSGGS- linker (SEQ ID NO:14).
- the linker is shorter. Instead of having the -GGSGGSGGS- linker (SEQ ID NO: 14), PreF_V2 has 2 glycines (-GG-) for linker.
- the G protein polypeptide domain can include all or part of a G protein selected from any RSV A or RSV B strain.
- the G protein is (or is 95% identical to) the G protein represented by SEQ ID NO:4. Additional examples of suitable G protein sequences can be found in WO2008114149 (which is incorporated herein by reference).
- the G protein polypeptide component is selected to include at least a subsequence (or fragment) of the G protein that retains the immunodominant T cell epitope(s), e.g., in the region of amino acids 183-197, such as fragments of the G protein that include amino acids 151-229, 149-229, or 128-229 of a native G protein.
- the G protein polypeptide is a subsequence (or fragment) of a native G protein polypeptide that includes all or part of amino acid residues 149 to 229 of a native G protein polypeptide.
- the G protein domain includes an amino acid substitution at position 191, which has previously been shown to be involved in reducing and/or preventing enhanced disease characterized by eosinophilia associated with formalin inactivated RSV vaccines.
- N191A naturally occurring and substituted G proteins
- one or more of the domains can correspond in sequence to an RSV A or B strain, such as the common laboratory isolates designated A2 or Long, or any other naturally occurring strain or isolate (as disclosed in the aforementioned WO2008114149).
- engineered variants that share sequence similarity with the aforementioned sequences can also be employed in the context of PreF (including PreF-G) antigens.
- sequence identity is frequently measured in terms of percentage identity (or similarity); the higher the percentage, the more similar are the primary structures of the two sequences. In general, the more similar the primary structures of two amino acid (or polynucleotide) sequences, the more similar are the higher order structures resulting from folding and assembly.
- Variants of a PreF polypeptide (and polynucleotide) sequences typically have one or a small number of amino acid deletions, additions or substitutions but will nonetheless share a very high percentage of their amino acid, and generally their polynucleotide sequence. More importantly, the variants retain the structural and, thus, conformational attributes of the reference sequences disclosed herein.
- NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. MoI. Biol. 215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.
- the PreF antigens has one or more amino acid modification relative to the amino acid sequence of the naturally occurring strain from which it is derived (e.g., in addition to the aforementioned stabilizing modifications). Such differences can be an addition, deletion or substitution of one or more amino acids.
- a variant typically differs by no more than about 1%, or 2%, or 5%, or 10%, or 15%, or 20% of the amino acid residues.
- a variant PreF antigen (including PreF-G) polypeptide sequence can include 1, or 2, or up to 5, or up to about 10, or up to about 15, or up to about 50, or up to about 100 amino acid differences as compared to the exemplary PreF antigen polypeptide sequences of SEQ ID NOs:6, 8, and/or 10.
- a variant in the context of an RSV F or G protein, or PreF antigen typically shares at least 80%, or 85%, more commonly, at least about 90% or more, such as 95%, or even 98% or 99% sequence identity with a reference protein, e.g. , the reference sequences illustrated in SEQ ID NO:2, 4, 6, 8 and/or 10, or any of the exemplary PreF antigens disclosed herein.
- a reference protein e.g. , the reference sequences illustrated in SEQ ID NO:2, 4, 6, 8 and/or 10, or any of the exemplary PreF antigens disclosed herein.
- Additional variants included as a feature of this disclosure are PreF antigens (including PreF-G antigens) that include all or part of a nucleotide or amino acid sequence selected from the naturally occurring variants disclosed in WO2008114149.
- Additional variants can arise through genetic drift, or can be produced artificially using site directed or random mutagenesis, or by recombination of two or more preexisting variants. Such additional variants are also suitable in the context of the PreF (and PreF-G) antigens disclosed herein.
- the modification can be a substitution of one or more amino acids (such as two amino acids, three amino acids, four amino acids, five amino acids, up to about ten amino acids, or more) that do not alter the conformation or immunogenic epitopes of the resulting PreF antigen.
- the modification can include a deletion of one or more amino acids and/or an addition of one or more amino acids.
- one or more of the polypeptide domains can be a synthetic polypeptide that does not correspond to any single strain, but includes component subsequences from multiple strains, or even from a consensus sequence deduced by aligning multiple strains of RSV virus polypeptides.
- one or more of the polypeptide domains is modified by the addition of an amino acid sequence that constitutes a tag, which facilitates subsequent processing or purification.
- a tag can be an antigenic or epitope tag, an enzymatic tag or a polyhistidine tag.
- the tag is situated at one or the other end of the protein, such as at the C-terminus or N-terminus of the antigen or fusion protein.
- nucleic acids that encode PreF antigens as described above.
- the recombinant nucleic acids are codon optimized for expression in a selected prokaryotic or eukaryotic host cell.
- SEQ ID NOs: 5 and 12 are two different illustrative, non-limiting, examples of sequences that encode a PreF antigen, which have been codon optimized for expression in mammalian, e.g., CHO, cells.
- the nucleic acids can be incorporated into a vector, such as a prokaryotic or a eukaryotic expression vector.
- Host cells including recombinant PreF antigen-encoding nucleic acids are also a feature of this disclosure.
- Favorable host cells include prokaryotic (i.e., bacterial) host cells, such as E. coli, as well as numerous eukaryotic host cells, including fungal (e.g., yeast) cells, insect cells, and mammalian cells (such as CHO, VERO and HEK293cells).
- the nucleic acids can be incorporated into a vector, such as a prokaryotic or a eukaryotic expression vector.
- a vector such as a prokaryotic or a eukaryotic expression vector.
- the nucleic acids disclosed herein can be included in any one of a variety of vectors (inclding, for example, bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, pseudorabies, adenovirus, adeno-associated virus, retroviruses and many others), most commonly the vector will be an expression vector suitable for generating polypeptide expression products.
- the nucleic acid encoding the PreF antigen is typically arranged in proximity and orientation to an appropriate transcription control sequence (promoter, and optionally, one or more enhancers) to direct mRNA synthesis. That is, the polynucleotide sequence of interest is operably linked to an appropriate transcription control sequence.
- promoters include: the immediate early promoter of CMV, LTR or SV40 promoter, polyhedrin promoter of baculovirus, E. coli lac or trp promoter, phage T7 and lambda P L promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.
- the expression vector typically also contains a ribosome binding site for translation initiation, and a transcription terminator.
- the vector optionally includes appropriate sequences for amplifying expression.
- the expression vectors optionally comprise one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as kanamycin, tetracycline or ampicillin resistance in E. coli.
- the expression vector can also include additional expression elements, for example, to improve the efficiency of translation.
- additional expression elements can include, e.g., an ATG initiation codon and adjacent sequences.
- a translation initiation codon and associated sequence elements are inserted into the appropriate expression vector simultaneously with the polynucleotide sequence of interest (e.g., a native start codon).
- additional translational control signals are not required.
- exogenous translational control signals including an ATG initiation codon is provided for translation of the nucleic acid encoding PreF antigen.
- the initiation codon is placed in the correct reading frame to ensure translation of the polynucleotide sequence of interest.
- Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. If desired, the efficiency of expression can be further increased by the inclusion of enhancers appropriate to the cell system in use (Scharf et al. (1994) Results Probl Cell Differ 20:125-62; Bitter et al. (1987) Methods in Enzvmol 153:516-544).
- the nucleic acid (such as a vector) that encodes the PreF antigen includes one or more additional sequence elements selected to increase and/or optimize expression of the PreF encoding nucleic acid when introduced into a host cell.
- the nucleic acids that encode the PreF antigen include an intron sequence, such as a Human Herpesvirus 5 intron sequence ⁇ see, e.g., SEQ ID NO: 13). Introns have been repeatedly demonstrated to enhance expression of homologous and heterologous nucleic acids when appropriately positioned in a recombinant construct.
- MAR Matrix Attachment Region
- STAR elements for example, such as those STAR elements disclosed in Otte et al, Biotechnol. Prog. 23:801-807, 2007
- MARs are believed to mediate the anchorage of a target DNA sequence to the nuclear matrix, generating chromatin loop domains that extend outwards from the heterochromatin cores. While MARs do not contain any obvious consensus or recognizable sequence, their most consistent feature appears to be an overall high A/T content, and C bases predominating on one strand.
- MAR sequences e.g., the A-box, the T-box, DNA unwinding motifs, SATBl binding sites (H-box, A/T/C25) and consensus Topoisomerase II sites for vertebrates or Drosophila.
- MAR sequences are described in published US patent application no. 20070178469, and in international patent application no. WO02/074969 (which are incorporated herein by reference).
- Additional MAR sequences that can be used to enhance expression of a nucleic acid encoding a PreF antigen include chicken lysozyme MAR, MARp 1-42, MARp 1-6, MARpI -68, and MARpx-29, described in Girod et al, Nature Methods, 4:747-753, 2007 (disclosed in GenBank Accession Nos. EA423306, DI107030, DI106196, DI107561, and DI106512, respectively).
- expression can further be modulated be selecting a MAR that produces an intermediate level of enhancement, as is reported for MAR 1-9.
- alternative MAR sequences for increasing expression of a PreF antigen can be identified by searching sequence databases, for example, using software such as MAR-Finder (available on the web at futuresoft.org/MarFinder), SMARTest (available on the web at genomatix.de), or SMARScan I (Levitsky et al, Bioinformat ⁇ cs 15:582-592, 1999).
- the MAR is introduced ⁇ e.g., transfected) into the host cell on the same nucleic acid ⁇ e.g., vector) as the PreF antigen-encoding sequence.
- the MAR is introduced on a separate nucleic acid ⁇ e.g., in trans) and it can optionally cointegrate with the PreF antigen-encoding polynucleotide sequence.
- nucleic acids that encode PreF antigen polypeptides are represented by SEQ ID NOs: 5, 7, 9, 12 and 13. Additional variants of can be produced by assembling analogous F and G protein polypeptide sequences selected from any of the known (or subsequently) discovered strains of RSV, e.g., as disclosed in WO2008114149. Additional sequence variants that share sequence identity with the exemplary variants can be produced by those of skill in the art. Typically, the nucleic acid variants will encode polypeptides that differ by no more than 1%, or 2%, or 5%, or 10%, or 15%, or 20% of the amino acid residues.
- the encoded polypeptides share at least 80%, or 85%, more commonly, at least about 90% or more, such as 95%, or even 98% or 99% sequence identity. It will be immediately understood by those of skill in the art, that the polynucleotide sequences encoding the PreF polypeptides, can themselves share less sequence identity due to the redundancy of the genetic code.
- the PreF antigens has one or more amino acid modification relative to the amino acid sequence of the naturally occurring strain from which it is derived (e.g., in addition to the aforementioned stabilizing modifications). Such differences can be an addition, deletion or substitution of one or more nucleotides or amino acids, respectively.
- a variant typically differs by no more than about 1%, or 2%, or 5%, or 10%, or.15%, or 20% or of the nucleotide residues.
- a variant PreF antigen (including PreF-G) nucleic acid can include 1, or 2, or up to 5, or up to about 10, or up to about 15, or up to about 50, or up to about 100 nucleotide differences as compared to the exemplary PreF antigen nucleic acids of SEQ ID NOs: 5, 7, 9, 12 and/or 13.
- a variant in the context of an RSV F or G protein, or PreF antigen (including PreF-G antigen) nucleic acid typically shares at least 80%, or 85%, more commonly, at least about 90% or more, such as 95%, or even 98% or 99% sequence identity with a reference sequence, e.g. t the reference sequences illustrated in SEQ ID NO:1, 3, 5, 7, 9, 12 or 13, or any of the other exemplary PreF antigen nucleic acids disclosed herein.
- Additional variants included as a feature of this disclosure are PreF antigens (including PreF-G antigens) that include all or part of a nucleotide sequence selected from the naturally occurring variants disclosed in WO2008114149.
- Additional variants can arise through genetic drift, or can be produced artificially using site directed or random mutagenesis, or by recombination of two or more preexisting variants. Such additional variants are also suitable in the context of the PreF (and PreF-G) antigens disclosed herein.
- nucleic acids that hybridize to one or more of the exemplary nucleic acids represented by SEQ ID NOs: 1, 3, 5, 7, 9, 12 and 13 can also be used to encode PreF antigens.
- SEQ ID NOs: 1, 3, 5, 7, 9, 12 and 13 can also be used to encode PreF antigens.
- Another indicia of sequence similarity between two nucleic acids is the ability to hybridize. The more similar are the sequences of the two nucleic acids, the more stringent the conditions at which they will hybridize. The stringency of hybridization conditions are sequence- dependent and are different under different environmental parameters.
- hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing nucleic acid sequences.
- the temperature of hybridization and the ionic strength (especially the Na + and/or Mg ⁇ concentration) of the hybridization buffer will determine the stringency of hybridization, though wash times also influence stringency.
- stringent conditions are selected to be about 5 0 C to 2O 0 C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
- the T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
- stringent conditions encompass conditions under which hybridization will only occur if there is less than 25% mismatch between the hybridization molecule and the target sequence.
- Stringent conditions can be broken down into particular levels of stringency for more precise definition.
- “moderate stringency” conditions are those under which molecules with more than 25% sequence mismatch will not hybridize; conditions of “medium stringency” are those under which molecules with more than 15% mismatch will not hybridize, and conditions of “high stringency” are those under which sequences with more than 10% mismatch will not hybridize.
- Conditions of "very high stringency” are those under which sequences with more than 6% mismatch will not hybridize.
- nucleic acids that hybridize under "low stringency conditions include those with much less sequence identity, or with sequence identity over only short subsequences of the nucleic acid. It will, therefore, be understood that the various variants of nucleic acids that are encompassed by this disclosure are able to hybridize to at least one of SEQ ID NOs: 1, 3, 5, 7, 9, and/or 12 over substantially their entire length.
- PreF antigens including PreF-G antigens, and also where applicacable, G antigens
- the PreF antigens disclosed herein are produced using well established procedures for the expression and purification of recombinant proteins. Procedures sufficient to guide one of skill in the art can be found in the following references: Sambrook et ah, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 200; and Ausubel et al. Short Protocols in Molecular Biology, 4 th ed., John Wiley & Sons, Inc., 999. Additional and specific details are provided hereinbelow.
- Recombinant nucleic acids that encode the PreF antigens are introduced into host cells by any of a variety of well-known procedures, such as electroporation, liposome mediated transfection ⁇ e.g., using a commercially available liposomal transfection reagent, such as LIPOFECTAMINETM2000 or TRANSFECTINTM), Calcium phosphate precipitation, infection, transfection and the like, depending on the selection of vectors and host cells.
- Exemplary nucleic acids that encode PreF antigens are provided in SEQ ID NOs:5, 7, 9, 12 and 13.
- SEQ ID NOs:5, 7, 9, 12 and 13 are illustrative and not intended to be limiting.
- polynucleotide sequences that encode the same proteins as SEQ ID NOs: 5, 7 and 9, e.g., represented by SEQ ID NOs: 6, 8 and 10
- polynucleotide sequences that include expression-enhancing elements, such as internally positioned introns (or by the addition of promoter, enhancer, intron or other similar elements), as illustrated in SEQ ID NO: 13, can be employed.
- expression-enhancing elements such as internally positioned introns (or by the addition of promoter, enhancer, intron or other similar elements), as illustrated in SEQ ID NO: 13, can be employed.
- homologous sequences selected from any RSV A or RSV B strain, and/or other sequences that share substantial sequence identity, as discussed above, can also be used to express PreF antigens.
- any of the variant nucleic acids previously disclosed can suitably be introduced into host cells and used to produce PreF antigens (including PreF-G antigens) and where applicable G polypeptides.
- Host cells that include recombinant PreF antigen-encoding nucleic acids are, thus, also a feature of this disclosure.
- Favorable host cells include prokaryotic (i.e., bacterial) host cells, such as E. coli, as well as numerous eukaryotic host cells, including fungal (e.g., yeast, such as Saccharomyces cerevisiae and Picchia pastoris) cells, insect cells, plant cells, and mammalian cells (such as CHO and HEK293 cells).
- Recombinant PreF antigen nucleic acids are introduced (e.g., transduced, transformed or transfected) into host cells, for example, via a vector, such as an expression vector.
- the vector is most typically a plasmid, but such vectors can also be, for example, a viral particle, a phage, etc.
- appropriate expression hosts include: bacterial cells, such as E. coli, Streptomyces, and Salmonella typhimurium; fungal cells, such as Saccharomyces cerevisiae, Pichia pastoris, and Neurospora crassa; insect cells such as Drosophila and Spodoptera frugiperda; mammalian cells such as 3T3, COS, CHO, BHK, HEK 293 or Bowes melanoma; plant cells, including algae cells, etc.
- the host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying the inserted polynucleotide sequences.
- the culture conditions such as temperature, pH and the like, are typically those previously used with the host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, e.g., Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein.
- Expression products corresponding to the nucleic acids of the invention can also be produced in non-animal cells such as plants, yeast, fungi, bacteria and the like.
- a number of expression vectors can be selected depending upon the use intended for the expressed product. For example, when large quantities of a polypeptide or fragments thereof are needed for the production of antibodies, vectors which direct high level expression of fusion proteins that are readily purified are favorably employed. Such vectors include, but are not limited to, multifunctional E.
- coli cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the coding sequence of interest, e.g., a polynucleotide of the invention as described above, can be ligated into the vector in-frame with sequences for the amino-terminal translation initiating Methionine and the subsequent 7 residues of beta-galactosidase producing a catalytically active beta galactosidase fusion protein; pIN vectors (Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509); pET vectors (Novagen, Madison WI), in which the amino-terminal methionine is ligated in frame with a histidine tag; and the like.
- BLUESCRIPT Stratagene
- yeast such as Saccharomyces cerevisiae
- a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH can be used for production of the desired expression products.
- constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH
- PGH protein oxidase
- a host cell is optionally chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion.
- modifications of the protein include, but are not limited to, glycosylation, (as well as, e.g., acetylation, carboxylation, phosphorylation, lipidation and acylation).
- Post-translational processing for example, which cleaves a precursor form into a mature form of the protein (for example, by a furin protease) is optionally performed in the context of the host cell.
- Different host cells such as 3T3, COS, CHO, HeLa, BHK, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and can be chosen to ensure the correct modification and processing of the introduced, foreign protein.
- PreF antigens disclosed herein For long-term, high-yield production of recombinant PreF antigens disclosed herein, stable expression systems are typically used. For example, cell lines which stably express a PreF antigen polypeptide are introduced into the host cell using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells are allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences.
- resistant groups or colonies of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.
- Host cells transformed with a nucleic acid encoding a PreF antigen are optionally cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture.
- the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
- the medium includes components and/or additives that decrease degradation of expressed proteins by proteinases.
- the medium used for culturing cells to produce PreF antigen can include a protease inhibitor, such as a chelating agent or small molecule inhibitor ⁇ e.g., AZl 1557272, ASl 11793, etc.), to reduce or eliminate undesired cleavage by cellular, or extracellular ⁇ e.g., matrix) proteinases.
- the secreted polypeptide product is then recovered from the culture medium.
- cells can be harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
- Eukaryotic or microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well know to those skilled in the art.
- Expressed PreF antigens can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, filtration, ultrafiltration, centrifugation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography (e.g., using any of the tagging systems noted herein), hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as desired, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed in the final purification steps.
- HPLC high performance liquid chromatography
- the nucleic acids are introduced into cells via vectors suitable for introduction and expression in prokaryotic cells, e.g., E. coli cells.
- a nucleic acid including a polynucleotide sequence that encodes a PreF antigen can be introduced into any of a variety of commercially available or proprietary vectors, such as the pET series of expression vectors ⁇ e.g., pET9b and pET2d). Expression of the coding sequence is inducible by IPTG, resulting in high levels of protein expression.
- the polynucleotide sequence encoding the PreF antigen is transcribed under the phage T7 promoter.
- Alternate vectors such as pURV22 that include a heat-inducible lambda pL promoter are also suitable.
- the expression vector is introduced (e.g., by electroporation) into a suitable bacterial host.
- suitable strains of E. coli are available and can be selected by one of skill in the art (for example, the Rosetta and BL21 (DE3) strains have proven favorable for expression of recombinant vectors containing polynucleotide sequences that encode PreF antigens.
- the polynucleotides that encode the PreF antigens are incorporated into expression vectors that are suitable for introduction and expression in eukaryotic (e.g., insect or mammalian cells).
- eukaryotic e.g., insect or mammalian cells
- such nucleic acids are codon optimized for expression in the selected vector/host cell (for example, the sequences illustrated in SEQ ID NOs:5, 7, 9 and 12 are codon optimized for expression in CHO cells).
- the polynucleotide sequence that encodes the PreF antigen is introduced into a vector, such as the pEE14 vector developped by Lonza Biologicals firm.
- the polypeptide is expressed under a constitutive promoter, such as the immediate early CMV (CytoMegaloVirus) promoter.
- Selection of the stably transfected cells expressing the polypeptide is made based on the ability of the transfected cells to grow in the absence of a glutamine source.
- Cells that have successfully integrated the pEE14 are able to grow in the absence of exogenous glutamine, because the pEE14 vector expresses the GS (Glutamine Synthetase) enzyme.
- Selected cells can be clonally expanded and characterized for expression of the desired PreF polypeptide.
- the polynucleotide sequence that encodes the PreF antigen is introduced into insect cells using a Baculovirus Expression Vector System (BEVS).
- BEVS Baculovirus Expression Vector System
- Recombinant baculovirus capable of infecting insect cells can be generated using commercially available vectors, kits and/or systems, such as the BD BaculoGold system from BD BioScience. Briefly, the polynucleotide sequence encoding the antigen is inserted into the pAcSG2 transfer vector.
- host cells SF9 (Spodoptera frugiperda) are co-transfected by pAcSG2-chimeric plasmid and BD BaculoGold, containing the linearized genomic DNA of the baculovirus A utograp ha calif ornica nuclear polyhedrosis virus (AcNPV).
- AcNPV baculovirus A utograp ha calif ornica nuclear polyhedrosis virus
- the PreF antigen is expressed under the regulatory control of the polyhedrin promoter (pH).
- Similar transfer vectors can be produced using other promoters, such as the basic (Ba) and plO promoters.
- alternative insect cells can be employed, such as SF21 which is closely related to the Sf9, and the High Five cell line derived from a cabbage looper, Trichoplusia ni.
- the expressed polypeptides are recovered (e.g., purified or enriched) and renatured to ensure folding into an antigenically active prefusion conformation.
- immunogenic compositions including any of the PreF antigens disclosed above (such as those exemplified by SEQ ID NOs: 6, 8 and 10) and a pharmaceutically acceptable carrier or excipient.
- the immunogenic composition can include an isolated, recombinant and/or purified G protein.
- G protein component such as SEQ ID NO:6
- suitable G proteins include full length recombinant G proteins and chimeric proteins made up of a portion of the G protein (such as amino acids 128-229 or 130-230) and a fusion partner (such as thioredoxin), or a signal and/or leader sequence, that facilitates expression and/or purification.
- Exemplary G proteins for use in admixture with a PreF antigen can be found in WO2008114149, US Patent No. 5,149,650, US Patent No.
- a smaller fragment of the G protein such as the portion between amino acids 149-229, or the portion between approximately 128 to approximately 229 can favorably be employed in the context of mixtures involving a PreF (without G) and G.
- the important consideration is the presence of immunodominant epitopes, e.g., included within the region of amino acids 183-197.
- a full-length G protein can be employed in such compositions.
- the carrier or excipient can favorably include a buffer.
- the carrier or excipient also contains at least one component that stabilizes solubility and/or stability.
- solubilizing/stabilizing agents include detergents, for example, laurel sarcosine and/or tween.
- Alternative solubilizing/stabilizing agents include arginine, and glass forming polyols (such as sucrose, trehalose and the like).
- Numerous pharmaceutically acceptable carriers and/or pharmaceutically acceptable excipients are known in the art and are described, e.g., in Remington 's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 5th Edition (975).
- suitable excipients and carriers can be selected by those of skill in the art to produce a formulation suitable for delivery to a subject by a selected route of administration.
- Suitable excipients include, without limitation: glycerol, Polyethylene glycol (PEG), Sorbitol, Trehalose, N-lauroylsarcosine sodium salt, L -proline, Non detergent sulfobetaine, Guanidine hydrochloride, Urea, Trimethylamine oxide, KCl, Ca 2+ , Mg 2+ , Mn 2+ , Zn 2+ and other divalent cation related salts, Dithiothreitol, Dithioerytrol, and ⁇ - mercaptoethanol.
- PEG Polyethylene glycol
- Sorbitol Sorbitol
- Trehalose N-lauroylsarcosine sodium salt
- L -proline Non detergent sulfobetaine
- Urea Trimethylamine oxide
- KCl Ca 2+ , Mg 2+ , Mn 2+ , Zn 2+ and other divalent cation related salts
- Dithiothreitol Dithio
- excipients can be detergents (including: Tween ⁇ O, Tween20, Triton X-OO, NP-40, Empigen BB, Octylglucoside, Lauroyl maltoside, Zwittergent 3-08, Zwittergent 3-0, Zwittergent 3-2, Zwittergent 3-4, Zwittergent 3-6, CHAPS, Sodium deoxycholate, Sodium dodecyl sulphate, Cetyltrimethylammonium bromide).
- detergents including: Tween ⁇ O, Tween20, Triton X-OO, NP-40, Empigen BB, Octylglucoside, Lauroyl maltoside, Zwittergent 3-08, Zwittergent 3-0, Zwittergent 3-2, Zwittergent 3-4, Zwittergent 3-6, CHAPS, Sodium deoxycholate, Sodium dodecyl sulphate, Cetyltrimethylammonium bromide).
- the immunogenic compositions also include an adjuvant.
- the adjuvant is selected to elicit a ThI biased immune response.
- the adjuvant is typically selected to enhance a ThI biased immune response in the subject, or population of subjects, to whom the composition is administered.
- the adjuvant is selected to be safe and effective in the subject or population of subjects.
- the adjuvant is selected to be safe and effective in elderly subjects.
- the adjuvant when the immunogenic composition containing the RSV PreF antigen is intended for administration in neonatal or infant subjects (such as subjects between birth and the age of two years), the adjuvant is selected to be safe and effective in neonates and infants. [0119] Additionally, the adjuvant is typically selected to enhance a ThI immune response when administered via a route of administration, by which the immunogenic composition is administered. For example, when formulating an immunogenic composition containing a PreF antigen for nasal administration, proteosome and protollin are favorable ThI- biasing adjuvants.
- adjuvants including one or more of 3 D-MPL, squalene (e.g., QS21), liposomes, and/or oil and water emulsions are favorably selected.
- One suitable adjuvant for use in combination with PreF antigens is a non-toxic bacterial lipopoly saccharide derivative.
- An example of a suitable non-toxic derivative of lipid A is monophosphoryl lipid A or more particularly 3-Deacylated monophoshoryl lipid A (3D-MPL).
- 3D-MPL is sold under the name MPL by GlaxoSmithKline Biologicals N.A., and is referred throughout the document as MPL or 3D-MPL. See, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094.
- 3D-MPL primarily promotes CD4+ T cell responses with an IFN- ⁇ (ThI) phenotype.
- 3 D-MPL can be produced according to the methods disclosed in GB2220211 A. Chemically it is a mixture of 3-deacylated monophosphoryl lipid A with 3, 4, 5 or 6 acylated chains. In the compositions of the present invention small particle 3D-MPL can be used. Small particle 3D-MPL has a particle size such that it can be sterile-filtered through a 0.22 ⁇ m filter. Such preparations are described in WO94/21292.
- a lipopolysaccharide such as 3D-MPL
- 3D-MPL can be used at amounts between 1 and 50 ⁇ g, per human dose of the immunogenic composition.
- 3D-MPL can be used at a level of about 25 ⁇ g, for example between 20-30 ⁇ g, suitably between 21-29 ⁇ g or between 22 and 28 ⁇ g or between 23 and 27 ⁇ g or between 24 and 26 ⁇ g, or 25 ⁇ g.
- the human dose of the immunogenic composition comprises 3D-MPL at a level of about lO ⁇ g, for example between 5 and 15 ⁇ g, suitably between 6 and 14 ⁇ g, for example between 7 and 13 ⁇ g or between 8 and 12 ⁇ g or between 9 and 1 l ⁇ g, or lO ⁇ g.
- the human dose of the immunogenic composition comprises 3D-MPL at a level of about 5 ⁇ g, for example between 1 and 9 ⁇ g, or between 2 and 8 ⁇ g or suitably between 3 and 7 ⁇ g or 4 and ⁇ g, or 5 ⁇ g.
- the lipopolysaccharide can be a ⁇ ( 1-6) glucosamine disaccharide, as described in US Patent No. 6,005,099 and EP Patent No. 0 729 473 Bl.
- One of skill in the art would be readily able to produce various lipopolysaccharides, such as 3D-MPL, based on the teachings of these references. Nonetheless, each of these references is incorporated herein by reference.
- acylated monosaccharide and disaccharide derivatives that are a sub-portion to the above structure of MPL are also suitable adjuvants.
- the adjuvant is a synthetic derivative of lipid A, some of which are described as TLR-4 agonists, and include, but are not limited to: OM 174 (2-deoxy-6-o-[2-deoxy-2-[(R)-3- dodecanoyloxytetra-decanoylamino]-4-o-phosphono- ⁇ -D-glucopyranosyl]-2-[(R)-3- hydroxytetradecanoylamino]- ⁇ -D-glucopyranosyldihydrogenphosphate), (WO 95/14026); OM 294 DP (3S, 9 R) -3--[(R)-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9(R)- [(R)-3-hydroxytetradecanoylamino]decan- 1 , 10-diol, 1 , 10-bis(dihydrogenophosphate) (WO 99/64301 and WO
- TLR4 ligands which can be used are alkyl Glucosaminide phosphates (AGPs) such as those disclosed in WO 98/50399 or US Patent No. 6,303,347 (processes for preparation of AGPs are also disclosed), suitably RC527 or RC529 or pharmaceutically acceptable salts of AGPs as disclosed in US Patent No. 6,764,840.
- AGPs alkyl Glucosaminide phosphates
- Some AGPs are TLR4 agonists, and some are TLR4 antagonists. Both are thought to be useful as adjuvants.
- TLR-4 ligands capable of causing a signaling response through TLR-4 (Sabroe et al, JI 2003 pi 630-5) are, for example, lipopolysaccharide from gram- negative bacteria and its derivatives, or fragments thereof, in particular a non-toxic derivative of LPS (such as 3D-MPL).
- suitable TLR agonists are: heat shock protein (HSP) 10, 60, 65, 70, 75 or 90; surfactant Protein A, hyaluronan oligosaccharides, heparan sulphate fragments, fibronectin fragments, fibrinogen peptides and b-defensin-2, and muramyl dipeptide (MDP).
- the TLR agonist is HSP 60, 70 or 90.
- Other suitable TLR-4 ligands are as described in WO 2003/011223 and in WO 2003/099195, such as compound I, compound II and compound III disclosed on pages 4-5 of WO2003/011223 or on pages 3-4 of WO2003/099195 and in particular those compounds disclosed in WO2003/011223 as ER803022, ER803058, ER803732, ER804053, ER804057, ER804058, ER804059, ER804442, ER804680, and ER804764.
- one suitable TLR-4 ligand is ER804057.
- TLR agonists are also useful as adjuvants.
- TLR agonist refers to an agent that is capable of causing a signaling response through a TLR signaling pathway, either as a direct ligand or indirectly through generation of endogenous or exogenous ligand.
- TLR agonists can be used as alternative or additional adjuvants.
- a brief review of the role of TLRs as adjuvant receptors is provided in Kaisho & Akira, Biochimica et Biophysica Acta 1589:1-13, 2002.
- These potential adjuvants include, but are not limited to agonists for TLR2, TLR3, TLR7, TLR8 and TLR9.
- the adjuvant and immunogenic composition further comprises an adjuvant which is selected from the group consisting of: a TLR-I agonist, a TLR-2 agonist, TLR-3 agonist, a TLR-4 agonist, TLR-5 agonist, a TLR-6 agonist, TLR-7 agonist, a TLR-8 agonist, TLR-9 agonist, or a combination thereof.
- an adjuvant which is selected from the group consisting of: a TLR-I agonist, a TLR-2 agonist, TLR-3 agonist, a TLR-4 agonist, TLR-5 agonist, a TLR-6 agonist, TLR-7 agonist, a TLR-8 agonist, TLR-9 agonist, or a combination thereof.
- a TLR agonist is used that is capable of causing a signaling response through TLR-I .
- the TLR agonist capable of causing a signaling response through TLR-I is selected from: Tri-acylated lipopeptides (LPs); phenol-soluble modulin; Mycobacterium tuberculosis LP; S-(2,3- bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys(4)-OH, trihydrochloride (Pam3Cys) LP which mimics the acetylated amino terminus of a bacterial lipoprotein and OspA LP from Borrelia burgdorferi.
- LPs Tri-acylated lipopeptides
- phenol-soluble modulin Mycobacterium tuberculosis LP
- a TLR agonist is used that is capable of causing a signaling response through TLR-2.
- the TLR agonist capable of causing a signaling response through TLR-2 is one or more of a lipoprotein, a peptidoglycan, a bacterial lipopeptide from M tuberculosis, B burgdorferi or T pallidum; peptidoglycans from species including Staphylococcus aureus; lipoteichoic acids, mannuronic acids, Neisseria porins, bacterial fimbriae, Yersina virulence factors, CMV virions, measles haemagglutinin, and zymosan from yeast.
- a TLR agonist is used that is capable of causing a signaling response through TLR-3.
- the TLR agonist capable of causing a signaling response through TLR-3 is double stranded RNA (dsRNA), or polyinosinic- polycytidylic acid (Poly IC), a molecular nucleic acid pattern associated with viral infection.
- dsRNA double stranded RNA
- Poly IC polyinosinic- polycytidylic acid
- a TLR agonist is used that is capable of causing a signaling response through TLR-5.
- the TLR agonist capable of causing a signaling response through TLR-5 is bacterial flagellin.
- a TLR agonist is used that is capable of causing a signaling response through TLR-6.
- the TLR agonist capable of causing a signaling response through TLR-6 is mycobacterial lipoprotein, di-acylated LP, and phenol-soluble modulin. Additional TLR6 agonists are described in WO 2003/043572.
- a TLR agonist is used that is capable of causing a signaling response through TLR-7.
- the TLR agonist capable of causing a signaling response through TLR-7 is a single stranded RNA (ssRNA), loxoribine, a guanosine analogue at positions N7 and C8, or an imidazoquinoline compound, or derivative thereof.
- the TLR agonist is imiquimod. Further TLR7 agonists are described in WO 2002/085905.
- a TLR agonist is used that is capable of causing a signaling response through TLR-8.
- the TLR agonist capable of causing a signaling response through TLR-8 is a single stranded RNA (ssRNA), an imidazoquinoline molecule with anti-viral activity, for example resiquimod (R848); resiquimod is also capable of recognition by TLR-7.
- ssRNA single stranded RNA
- R848 imidazoquinoline molecule with anti-viral activity
- resiquimod is also capable of recognition by TLR-7.
- Other TLR-8 agonists which can be used include those described in WO 2004/071459.
- a TLR agonist is used that is capable of causing a signaling response through TLR-9.
- the TLR agonist capable of causing a signaling response through TLR-9 is HSP90.
- the TLR agonist capable of causing a signaling response through TLR-9 is bacterial or viral DNA, DNA containing unmethylated CpG nucleotides, in particular sequence contexts known as CpG motifs.
- CpG-containing oligonucleotides induce a predominantly ThI response.
- Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462.
- CpG nucleotides are CpG oligonucleotides.
- Suitable oligonucleotides for use in the immunogenic compositions of the present invention are CpG containing oligonucleotides, optionally containing two or more dinucleotide CpG motifs separated by at least three, suitably at least six or more nucleotides.
- a CpG motif is a Cytosine nucleotide followed by a Guanine nucleotide.
- the CpG oligonucleotides of the present invention are typically deoxynucleotides.
- the internucleotide in the oligonucleotide is phosphorodithioate, or suitably a phosphorothioate bond, although phosphodiester and other internucleotide bonds are within the scope of the invention.
- oligonucleotides with mixed internucleotide linkages are included within the scope of the invention. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in US Patent Nos. 5,666,153, 5,278,302 and WO 95/26204.
- compositions with a PreF antigens e.g., on their own or in combination with 3D-MPL, or another adjuvant described herein, are saponins, such as QS21.
- Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. Phytomedicine vol 2 pp 363-386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins.
- Saponins are known as adjuvants in vaccines for systemic administration.
- the adjuvant and haemolytic activity of individual saponins has been extensively studied in the art (Lacaille-Dubois and Wagner, supra).
- Quil A derived from the bark of the South American tree Quillaja Saponaria Molina
- Serreins as vaccine adjuvants
- Kensil, C. R. Crit Rev Ther Drug Carrier Syst, 1996, 12 (l-2):l-55
- EP 0 362 279 Bl are known as adjuvants in vaccines for systemic administration.
- IMS Immune Stimulating Complexes
- Quil A fractions of Quil A are haemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 Bl ; WO 96/11711 ; WO 96/33739).
- the haemolytic saponins QS21 and QS17 HPLC purified fractions of Quil A have been described as potent systemic adjuvants, and the method of their production is disclosed in US Patent No.5,057,540 and EP 0 362 279 Bl, which are incorporated herein by reference.
- QS21 is an HpIc purified non-toxic fraction derived from the bark of Quillaja Saponaria Molina.
- a method for producing QS21 is disclosed in US Patent No. 5,057,540.
- Non-reactogenic adjuvant formulations containing QS21 are described in WO 96/33739. The aforementioned references are incorporated by reference herein.
- Said immunologically active saponin, such as QS21 can be used in amounts of between 1 and 50 ⁇ g, per human dose of the immunogenic composition.
- QS21 is used at a level of about 25 ⁇ g, for example between 20-30 ⁇ g, suitably between 2 l-29 ⁇ g or between 22 -28 ⁇ g or between 23 -27 ⁇ g or between 24 -26 ⁇ g, or 25 ⁇ g.
- the human dose of the immunogenic composition comprises QS21 at a level of about lO ⁇ g, for example between 5 and 15 ⁇ g, suitably between 6 -14 ⁇ g, for example between 7 -13 ⁇ g or between 8 -12 ⁇ g or between 9 -11 ⁇ g, or lO ⁇ g.
- the human dose of the immunogenic composition comprises QS21 at a level of about 5 ⁇ g, for example between l-9 ⁇ g, or between 2 -8 ⁇ g or suitably between 3-7 ⁇ g or 4 -6 ⁇ g, or 5 ⁇ g.
- QS21 and cholesterol have been shown to be successful ThI stimulating adjuvants when formulated together with an antigen.
- PreF polypeptides can favorably be employed in immunogenic compositions with an adjuvant comprising a combination of QS21 and cholesterol.
- the adjuvant can also include mineral salts such as an aluminium or calcium salts, in particular aluminium hydroxide, aluminium phosphate and calcium phosphate.
- mineral salts such as an aluminium or calcium salts, in particular aluminium hydroxide, aluminium phosphate and calcium phosphate.
- an adjuvant containing 3 D-MPL in combination with an aluminium salt e.g., aluminium hydroxide or "alum" is suitable for formulation in an immunogenic composition containing a PreF antigen for administration to a human subject.
- OMP-based immunostimulatory compositions are particularly suitable as mucosal adjuvants, e.g., for intranasal administration.
- OMP-based immunostimulatory compositions are a genus of preparations of outer membrane proteins (OMPs, including some porins) from Gram- negative bacteria, such as, but not limited to, Neisseria species (see, e.g., Lowell et al, J. Exp. Med. 167:658, 1988; Lowell et al, Science 240:800, 1988; Lynch et al, Biophys. J.
- OMP-based immunostimulatory compositions can be referred to as "Proteosomes," which are hydrophobic and safe for human use.
- Proteosomes have the capability to auto-assemble into vesicle or vesicle-like OMP clusters of about 20 nm to about 800 nm, and to noncovalently incorporate, coordinate, associate ⁇ e.g., electrostatically or hydrophobically), or otherwise cooperate with protein antigens (Ags), particularly antigens that have a hydrophobic moiety.
- protein antigens Ags
- Proteosomes can be prepared, for example, as described in the art (see, e.g. , U.S. Pat. No. 5,726,292 or U.S. Pat. No. 5,985,284). Proteosomes can also contain an endogenous lipopolysaccharide or lipooligosaccharide (LPS or LOS, respectively) originating from the bacteria used to produce the OMP porins ⁇ e.g., Neisseria species), which generally will be less than 2% of the total OMP preparation.
- LPS lipopolysaccharide
- LOS lipooligosaccharide
- Proteosomes are composed primarily of chemically extracted outer membrane proteins (OMPs) from Neisseria menigitidis (mostly porins A and B as well as class 4 OMP), maintained in solution by detergent (Lowell GH. Proteosomes for Improved Nasal, Oral, or Injectable Vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds, New Generation Vaccines. New York: Marcel Dekker, Inc. 1997; 193-206).
- OMPs outer membrane proteins
- Proteosomes can be formulated with a variety of antigens such as purified or recombinant proteins derived from viral sources, including the PreF polypeptides disclosed herein, e.g., by diafiltration or traditional dialysis processes. The gradual removal of detergent allows the formation of particulate hydrophobic complexes of approximately 100-200nm in diameter (Lowell GH. Proteosomes for Improved Nasal, Oral, or Injectable Vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds, New Generation Vaccines. New York: Marcel Dekker, Inc. 1997; 193-206).
- Protosome LPS or Protollin
- the OMP-LPS composition can be comprised of two of the basic components of Protollin, which include (1) an outer membrane protein preparation of Proteosomes ⁇ e.g., Projuvant) prepared from Gram-negative bacteria, such as Neisseria meningitidis, and (2) a preparation of one or more liposaccharides.
- a lipo- oligosaccharide can be endogenous (e.g., naturally contained with the OMP Proteosome preparation), can be admixed or combined with an OMP preparation from an exogenously prepared lipo-oligosaccharide (e.g., prepared from a different culture or microorganism than the OMP preparation), or can be a combination thereof.
- exogenously added LPS can be from the same Gram-negative bacterium from which the OMP preparation was made or from a different Gram-negative bacterium.
- Protollin should also be understood to optionally include lipids, glycolipids, glycoproteins, small molecules, or the like, and combinations thereof.
- the Protollin can be prepared, for example, as described in U.S. Patent Application Publication No. 2003/0044425.
- Combinations of different adjuvants can also be used in compositions with PreF antigens.
- QS21 can be formulated together with 3D-MPL.
- the ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; such as 1 :5 to 5 : 1, and often substantially 1 : 1.
- the ratio is in the range of 2.5 : 1 to 1 : 1 3D-MPL: QS21.
- Another combination adjuvant formulation includes 3D-MPL and an aluminium salt, such as aluminium hydroxide. When formulated in combination, this combination can enhance an antigen-specific ThI immune response.
- the adjuvant formulation includes an oil-in- water emulsion, or a mineral salt such as a calcium or aluminium salt, for example calcium phosphate, aluminium phosphate or aluminium hydroxide.
- a mineral salt such as a calcium or aluminium salt, for example calcium phosphate, aluminium phosphate or aluminium hydroxide.
- an oil-in- water emulsion comprises a metabolisable oil, such as squalene, a tocol such as a tocopherol, e.g., alpha-tocopherol, and a surfactant, such as polysorbate 80 or Tween 80, in an aqueous carrier, and does not contain any additional immunostimulants(s), in particular it does not contain a non-toxic lipid A derivative (such as 3D-MPL) or a saponin (such as QS21).
- the aqueous carrier can be, for example, phosphate buffered saline.
- the oil-in-water emulsion can contain span 85 and/or lecithin and/or tricaprylin.
- a vaccine composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil-in-water emulsion and optionally one or more further immunostimulants, wherein said oil-in-water emulsion comprises 0.5-10 mg metabolisable oil (suitably squalene), 0.5-11 mg tocol (suitably a tocopherol, such as alpha-tocopherol) and 0.4-4 mg emulsifying agent.
- said oil-in-water emulsion comprises 0.5-10 mg metabolisable oil (suitably squalene), 0.5-11 mg tocol (suitably a tocopherol, such as alpha-tocopherol) and 0.4-4 mg emulsifying agent.
- the adjuvant formulation includes 3D-MPL prepared in the form of an emulsion, such as an oil-in- water emulsion.
- the emulsion has a small particle size of less than 0.2 ⁇ m in diameter, as disclosed in WO 94/21292.
- the particles of 3D-MPL can be small enough to be sterile filtered through a 0.22micron membrane (as described in European Patent number 0 689454).
- the 3D-MPL can be prepared in a liposomal formulation.
- the adjuvant containing 3 D-MPL (or a derivative thereof) also includes an additional immunostimulatory component.
- the dosage of adjuvant is determined to be effective and relatively non-reactogenic in an infant subject.
- the dosage of adjuvant in an infant formulation is lower than that used in formulations designed for administration to adult (e.g., adults aged 65 or older).
- the amount of 3D- MPL is typically in the range of l ⁇ g-200 ⁇ g, such as 10-100 ⁇ g, or 10 ⁇ g-50 ⁇ g per dose.
- An infant dose is typically at the lower end of this range, e.g., from about l ⁇ g to about 50 ⁇ g, such as from about 2 ⁇ g, or about 5 ⁇ g, or about lO ⁇ g, to about 25 ⁇ g, or to about 50 ⁇ g.
- the ranges are comparable (and according to the ratios indicated above).
- the formulations typically include more of an adjuvant component than is typically found in an infant formulation.
- such an emulsion can include additional components, for example, such as cholesterol, squalene, alpha tocopherol, and/or a detergent, such as tween 80 or span85.
- such components can be present in the following amounts: from about 1- 50mg cholesterol, from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80.
- the ratio of squalene: alpha tocopherol is equal to or less than 1 as this provides a more stable emulsion.
- the formulation can also contain a stabilizer.
- alum is present, e.g., in combination with 3D-MPL, the amount is typically between about lOO ⁇ g and lmg, such as from about lOO ⁇ g, or about 200 ⁇ g to about 750 ⁇ g, such as about 500 ⁇ g per dose.
- An immunogenic composition typically contains an immunoprotective quantity (or a fractional dose thereof) of the antigen and can be prepared by conventional techniques. Preparation of immunogenic compositions, including those for administration to human subjects, is generally described in Pharmaceutical Biotechnology, Vol.61 Vaccine Design-the subunit and adjuvant approach, edited by Powell and Newman, Plenum Press, 1995. New Trends and Developments in Vaccines, edited by Voller et al, University Park Press, Baltimore, Maryland, U.S.A. 1978. Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, U.S. Patent 4,372,945 and by Armor et al, U.S. Patent 4,474,757.
- the amount of protein in each dose of the immunogenic composition is selected as an amount which induces an immunoprotective response without significant, adverse side effects in the typical subject.
- Immunoprotective in this context does not necessarily mean completely protective against infection; it means protection against symptoms or disease, especially severe disease associated with the virus.
- the amount of antigen can vary depending upon which specific immunogen is employed.
- each human dose will comprise l-1000 ⁇ g of protein, such as from about l ⁇ g to about lOO ⁇ g, for example, from about l ⁇ g to about 50 ⁇ g, such as about l ⁇ g, about 2 ⁇ g, about 5 ⁇ g, about lO ⁇ g, about 15 ⁇ g, about 20 ⁇ g, about 25 ⁇ g, about 30 ⁇ g, about 40 ⁇ g, or about 50 ⁇ g.
- the amount utilized in an immunogenic composition is selected based on the subject population ⁇ e.g. , infant or elderly). An optimal amount for a particular composition can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects can receive a boost in about 4 weeks.
- the concentration in the final formulation is calculated to be safe and effective in the target population.
- immunogenic compositions for eliciting an immune response against RSV in humans are favorably administered to infants (e.g., infants between birth and 1 year, such as between 0 and 6 months, at the age of initial dose).
- Immunogenic compositions for eliciting an immune response against RSV are also favorably administered to elderly humans (e.g., alone or in a combination with antigens of other pathogens associated with COPD). It will be appreciated that the choice of adjuvant can be different in these different applications, and the optimal adjuvant and concentration for each situation can be determined empirically by those of skill in the art.
- the immunogenic compositions are vaccines that reduce or prevent infection with RSV.
- the immunogenic compositions are vaccines that reduce or prevent a pathological response following infection with RSV.
- the immunogenic compositions containing a PreF antigen are formulated with at least one additional antigen of a pathogenic organism other than RSV.
- the pathogenic organism can be a pathogen of the respiratory tract (such as a virus or bacterium that causes a respiratory infection).
- the immunogenic composition contains an antigen derived from a pathogenic virus other than RSV, such as a virus that causes an infection of the respiratory tract, such as influenza or parainfluenza.
- the additional antigens are selected to facilitate administration or reduce the number of inoculations required to protect a subject against a plurality of infectious organisms.
- the antigen can be derived from any one or more of influenza, hepatitis B, diphtheria, tetanus, pertussis, Hemophilus influenza, poliovirus, Streptococcus or Pneumococcus, among others.
- PreF antigens or nucleic acids that encode them in the preparation of a medicament for treating (either therapeutically following or prophylactically prior to) exposure to or infection by RSV is also a feature of this disclosure.
- methods for eliciting an immune response against RSV in a subject are a feature of this disclosure. Such methods include administering an immunologically effective amount of a composition comprising a PreF antigen to a subject, such as a human subject.
- the composition includes an adjuvant that elicits a ThI biased immune response.
- the composition is formulated to elicit an immune response specific for RSV without enhancing viral disease following contact with RSV.
- the composition is formulated to and results in a ThI biased immune response that reduces or prevents infection with a RSV and/or reduces or prevents a pathological response following infection with a RSV.
- the composition can be administered by a variety of different routes, most commonly, the immunogenic compositions are delivered by an intramuscular or intranasal route of administration.
- An immunogenic composition typically contains an immunoprotective quantity (or a fractional dose thereof) of the antigen and can be prepared by conventional techniques. Preparation of immunogenic compositions, including those for administration to human subjects, is generally described in Pharmaceutical Biotechnology, Vol.61 Vaccine Design-the subunit and adjuvant approach, edited by Powell and Newman, Plenum Press, 1995. New Trends and Developments in Vaccines, edited by Voller et al, University Park Press, Baltimore, Maryland, U.S.A. 1978. Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, U.S. Patent 4,372,945 and by Armor et al, U.S. Patent 4,474,757.
- the amount of protein in each dose of the immunogenic composition is selected as an amount which induces an immunoprotective response without significant, adverse side effects in the typical subject.
- Immunoprotective in this context does not necessarily mean completely protective against infection; it means protection against symptoms or disease, especially severe disease associated with the virus.
- the amount of antigen can vary depending upon which specific immunogen is employed.
- each human dose will comprise 1 lOOO ⁇ g of protein, such as from about l ⁇ g to about lOO ⁇ g, for example, from about l ⁇ g to about 50 ⁇ g, such as about l ⁇ g, about 2 ⁇ g, about 5 ⁇ g, about lO ⁇ g, about 15 ⁇ g, about 20 ⁇ g, about 25 ⁇ g, about 30 ⁇ g, about 40 ⁇ g, or about 50 ⁇ g.
- the amount utilized in an immunogenic composition is selected based on the subject population ⁇ e.g., infant or elderly). An optimal amount for a particular composition can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects can receive a boost in about 4-12 weeks. For example, when administering an immunogenic composition containing a PreF antigen to an infant subject, the initial and subsequent inoculations can be administered to coincide with other vaccines administered during this period.
- Example 1 Exemplary PreF antigens
- the PreF antigen was modified as compared to a native RSV F protein in order to stabilize the protein in its prefusion conformation, based on the prediction that an immune response generated to the prefusion conformation of F would preferentially include antibodies that would prevent binding, conformation shifting and/or other events involved in membrane fusion, thereby increasing the efficacy of the protective response.
- FIG. IA and B schematically illustrate features of RSV FO and exemplary PreF recombinant antigens.
- FIG. IA is a representation of the RSV FO protein.
- FO is a pre- protein consisting of 574 amino acids.
- the FO pre-protein is proteolytically processed and glycosylated following translation.
- a signal peptide which is later removed by a signal peptidase, targets translation of the FO pre-protein to the reticulum endoplasmic (RE). Nascent peptide in the RE is then N-glycosylated at multiple sites (represented by triangles).
- Furin cleavage of FO generates F2 and Fl peptide domains, which are folded and assembled together as a trimer of F2-F1 heterodimers (that is, 3 times F2-F1).
- the F protein In its native state, the F protein is anchored to the membrane by a transmembrane helix in the C- terminal region. Additional features of the FO polypeptide include, 15 Cysteine residues, 4 characterized neutralizing epitopes, 2 coiled-coil regions, and a lipidation motif.
- FIG. IB illustrates features of exemplary PreF antigens.
- the FO polypeptide was modified to stabilize the prefusion conformation of the F protein, thereby retaining the predominant immunogenic epitopes of the F protein as presented by the RSV virus prior to binding to and fusion with host cells.
- the following stabilizing mutations were introduced into the PreF antigen relative to the FO polypeptide.
- a stabilizing coiled-coil domain was placed at the C-terminal end of the extracellular domain of the FO polypeptide, replacing the membrane anchoring domain of FO.
- the pep27 peptide was removed.
- both furin motifs were eliminated.
- an immunologically active portion e.g., amino acids 149-229 of the RSV G protein was added to the C-terminal domain.
- Example 2 Production and Purification of PreF recombinant protein from CHO cells.
- a recombinant polynucleotide sequence encoding an exemplary PreF antigen was introduced into host CHO cells for the production of PreF antigen.
- Transiently transfected host cells or expanded stable populations comprising the introduced polynucleotide sequence were grown in medium and under conditions suitable for growth at an acceptable scale for the desired purpose (e.g., as generally described in Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein).
- the cells were grown in serum-free medium in shake flasks at 37°C with 5% CO 2 and passaged at 2-3 day intervals, or in bioreactors at 29 0 C with pO2 maintained at 20%.
- the cell culture was centrifuged and the cell culture supernatant stored at 80 0 C until further use.
- two liter aliquots of cell culture supernatant were diluted 2x with purified water and adjusted to pH 9.5 with NaOH.
- the supernatant was loaded at a rate of 14 ml/min. onto a Q Sepharose FF ion exchange column (60 ml, 11.3 cm), equilibrated in 20 mM piperazine pH 9.5. After washing the column with the starting buffer, elution was performed with a NaCl gradient from 0 to 0.5 M NaCl in 20 column volumes (fraction size 10 ml). Fractions were analyzed on SDS PAGE gel by silver staining and western blot. Fractions containing substantial PreF protein were then pooled prior to further processing.
- Example 3 Characterization of the PreF recombinant protein produced in CHQ cells.
- PreF recombinant protein produced in CHO cells was characterized by asymmetrical field flow fractionation (AFF-MALS) and compared to a chimeric antigen including RSV F and G protein components.
- AFF-MALS allows separation of protein species according to their molecular size in a liquid flow with minimal matrix interaction and further analysis by multi-angle light scattering for accurate molecular weight determination.
- FIG. 2A shows that more than 65% of purified FG material is found as high molecular weight oligomers (1000-100 000 KDa) in is final PBS buffer while 3% remain in monomeric form.
- FIG. 2B shows that the purified PreF protein is folded in his trimeric form to a proportion of 73% in PBS buffer. 10% of the material is found as 1000 to 20 000 KDa oligomers.
- Purified PreF protein was also crosslinked with glutaraldehyde for the double purpose of confirming the soluble nature of the protein in phosphate buffer solution and of generating aggregates for comparative in vivo evaluation with FG protein (see Example 7 below).
- Glutaraldehyde crosslinking is known for providing a good assessment of the quaternary structure of a protein, and is described in (Biochemistry, 36:10230-10239 (1997); Eur. J. Biochem., 271 :4284-4292 (2004)).
- mice were immunized twice IM at two weeks interval with preF (6.5, 3.1, 0.63, 0.13, and 0.025 ⁇ g/ml) and a ThI adjuvant containing 3D MPL and QS21 at 1/20 of human dose ("ASOlE") or preF (1, 0.2 and 0.04 ⁇ g/ml) and a ThI adjuvant containing 3D MPL and alum 1/10 of human dose (“AS04C”) and serum was collected three weeks later.
- preF 6.5, 3.1, 0.63, 0.13, and 0.025 ⁇ g/ml
- ASOlE ThI adjuvant containing 3D MPL and QS21 at 1/20 of human dose
- AS04C ThI adjuvant containing 3D MPL and alum 1/10 of human dose
- Antigen-specific IgG antibody titers were determined on pooled serum samples by ELISA according to standard procedures. Briefly, 96-well plates were coated with purified inactivated RSV A, RSV B and homologous preF protein and incubated overnight at 4°C. Serum samples were serially diluted in blocking buffer starting at an initial concentration of 1 : 50, along with purified mouse IgG Sigma, ON) at starting concentrations of 200 ng/ml and incubated for 2h at room temperature. Bound antibody was detected with horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Sigma, ON).
- HRP horseradish peroxidase
- TMB 3,3A,5,5A-tetramethylbenzidine
- BD Opt EIATM 3,3A,5,5A-tetramethylbenzidine
- HRP HRP
- 50 ⁇ l of IM H2SO4 was added to each well to stop the reaction. Absorbance values for each well were detected at 450 nm with a Molecular Devices microplate reader (Molecular Devices, USA).
- FIGS. 4A and 4B show that strong titers are elicited against both RSV A and RSV B following immunization with preF antigen.
- mice immunized as described above in Example 5 The presence and quantity of neutralizing antibodies was assessed in serum samples of mice immunized as described above in Example 5. Pooled sera from immunized animals were serially diluted from a starting dilution of 1 :8 in RSV medium in 96-well plates (20 ⁇ l/well). Control wells contained RSV medium only, or goat anti-RSV antibody at 1 :50 (Biodesign international). 500-1000 infectious doses of a representative RSV A or B strain were added to the wells, and the plates were incubated for 20 minutes at 33 0 C, 5% CO 2 , before the mixture was transferred to 96-well flat-bottomed plates previously seeded with 1x10 5 cells/mL Vero cells.
- mice were immunized twice IM at a two week interval as described above, and challenged three weeks after the second injection with RSV A. Protection against RSV was evaluated by measuring the virus present in lungs following challenge. In brief, lungs from immunized animals were aseptically removed following euthanasia and washed in RSV medium using 2 volumes of 10 ml/lung in 15 ml tubes. Lungs were then weighed and homogenized individually in RSV medium with an automated Potter homogenizer (Fisher, Nepean ON), and centrifuged at 2655 x g for 2 minutes at 4 0 C.
- an automated Potter homogenizer Fisher, Nepean ON
- the virus present in the supernatants was titered by serial dilution (eight replicates starting at 1 : 10) on a previously seeded Vero cell (ATCC# CCL-81) monolayer in 96- well plates and incubated for 6 days.
- RSV was detected by indirect IFA following fixing in 1% paraformaldehyde/PBS pH7.2, with goat anti-RSV primary antibody and FITC labeled anti-goat IgG secondary antibody.
- Example 8 PreF does not induce pulmonary eosinophil recruitment following challenge
- mice/group mice were immunized twice each with (a) 10 ⁇ g gluteraldehyde-treated preF, (b) 10 ⁇ g preF or (c) 10 ⁇ g FG without adjuvant.
- Mice were challenged with RSV A 3 weeks post-boost and bronchoalveolar lavage (BAL) was performed 4 days post challenge.
- BAL bronchoalveolar lavage
- Exemplary coiled-coil isoleucine zipper
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010007107A MX2010007107A (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens. |
EA201070794A EA021393B1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
DK08864495.0T DK2222710T3 (en) | 2007-12-24 | 2008-12-23 | Recombinant RSV antigens. |
JP2010539977A JP5711972B2 (en) | 2007-12-24 | 2008-12-23 | Recombinant RSV antigen |
ES08864495.0T ES2597439T3 (en) | 2007-12-24 | 2008-12-23 | RSV recombinant antigens |
EP08864495.0A EP2222710B8 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
EP22181399.1A EP4108688A1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
EP16180926.4A EP3109258B1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
EP22211934.9A EP4206231A1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
LTEP08864495.0T LT2222710T (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
EP19152924.7A EP3508505A1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
RS20160792A RS55162B1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
US12/810,196 US8563002B2 (en) | 2007-12-24 | 2008-12-23 | Recombinant RSV antigens |
EP22181398.3A EP4108687A1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
BRPI0821532-4A BRPI0821532A2 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
CN200880127407.3A CN101952321B (en) | 2007-12-24 | 2008-12-23 | Recombinant RSV incorporate antigen |
SI200831685A SI2222710T1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
EP23150323.6A EP4219566A3 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
AU2008340949A AU2008340949A1 (en) | 2007-12-24 | 2008-12-23 | Recombinant RSV antigens |
CA2710600A CA2710600C (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
ZA2010/04289A ZA201004289B (en) | 2007-12-24 | 2010-06-17 | Recombinant rsv antigens |
CY20161101010T CY1118090T1 (en) | 2007-12-24 | 2016-10-11 | Recombinant RSV antigens |
HRP20161353TT HRP20161353T1 (en) | 2007-12-24 | 2016-10-17 | Recombinant rsv antigens |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1652407P | 2007-12-24 | 2007-12-24 | |
US61/016,524 | 2007-12-24 | ||
US5620608P | 2008-05-27 | 2008-05-27 | |
US61/056,206 | 2008-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009079796A1 true WO2009079796A1 (en) | 2009-07-02 |
Family
ID=40800629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2008/002277 WO2009079796A1 (en) | 2007-12-24 | 2008-12-23 | Recombinant rsv antigens |
Country Status (23)
Country | Link |
---|---|
US (1) | US8563002B2 (en) |
EP (7) | EP3508505A1 (en) |
JP (1) | JP5711972B2 (en) |
KR (1) | KR101617895B1 (en) |
CN (1) | CN101952321B (en) |
AU (1) | AU2008340949A1 (en) |
BR (1) | BRPI0821532A2 (en) |
CA (1) | CA2710600C (en) |
CY (1) | CY1118090T1 (en) |
DK (1) | DK2222710T3 (en) |
EA (1) | EA021393B1 (en) |
ES (2) | ES2597439T3 (en) |
HR (1) | HRP20161353T1 (en) |
HU (1) | HUE029258T2 (en) |
LT (1) | LT2222710T (en) |
MX (1) | MX2010007107A (en) |
PL (1) | PL2222710T3 (en) |
PT (1) | PT2222710T (en) |
RS (1) | RS55162B1 (en) |
SG (1) | SG188813A1 (en) |
SI (1) | SI2222710T1 (en) |
WO (1) | WO2009079796A1 (en) |
ZA (1) | ZA201004289B (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010006447A1 (en) * | 2008-07-18 | 2010-01-21 | Id Biomedical Corporation Of Quebec | Chimeric respiratory syncytial virus polypeptide antigens |
WO2010149745A1 (en) * | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
WO2010149743A3 (en) * | 2009-06-24 | 2011-03-10 | Id Biomedical Corporation Of Quebec | Vaccine |
WO2011008974A3 (en) * | 2009-07-15 | 2011-04-28 | Novartis Ag | Rsv f protein compositions and methods for making same |
WO2011050168A3 (en) * | 2009-10-21 | 2011-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
CN102294027A (en) * | 2011-07-26 | 2011-12-28 | 昆明理工大学 | Respiratory syncytial virus F2 protein subunit vaccine and preparation method thereof |
WO2012048115A3 (en) * | 2010-10-06 | 2012-06-21 | University Of Washington Through Its Center For Commercialization | Polypeptides and their use in treating and limiting respiratory syncytial virus infection |
WO2012158613A1 (en) | 2011-05-13 | 2012-11-22 | Novartis Ag | Pre-fusion rsv f antigens |
WO2013006842A2 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
WO2013031827A1 (en) | 2011-08-29 | 2013-03-07 | 国立大学法人徳島大学 | Rsv mucosal vaccine |
WO2014079842A1 (en) * | 2012-11-20 | 2014-05-30 | Novartis Ag | Rsv f prefusion trimers |
WO2014160463A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
US20150166610A1 (en) * | 2013-10-14 | 2015-06-18 | Glaxosmithkline Biologicals, S.A. | Recombinant rsv antigens |
JP2016028088A (en) * | 2009-07-17 | 2016-02-25 | インダストリー アカデミック コーポレーション ファウンデーション, ハルリム ユニバーシティー | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes |
WO2016203052A1 (en) * | 2015-06-18 | 2016-12-22 | Vib Vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
EP3124042A1 (en) * | 2015-07-28 | 2017-02-01 | VIB, vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
US9701720B2 (en) | 2012-04-05 | 2017-07-11 | University Of Washington Through Its Center For Commercialization | Epitope-scaffold immunogens against respiratory syncytial virus (RSV) |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US9950058B2 (en) | 2015-12-23 | 2018-04-24 | Pfizer Inc. | RSV F protein mutants |
WO2018114892A1 (en) | 2016-12-20 | 2018-06-28 | Glaxosmithkline Biologicals S.A. | Novel methods for inducing an immune response |
WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018219521A1 (en) | 2017-05-30 | 2018-12-06 | Glaxosmithkline Biologicals S.A. | Methods for manufacturing an adjuvant |
US10294279B2 (en) | 2013-06-17 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
EP3488864A1 (en) | 2013-04-25 | 2019-05-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
WO2019106192A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
US10456462B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Preventions B.V. | Vaccine against RSV |
WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
WO2020099383A1 (en) | 2018-11-13 | 2020-05-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US10729757B2 (en) | 2016-04-05 | 2020-08-04 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
EP3808374A1 (en) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection |
US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
WO2022070129A1 (en) | 2020-10-02 | 2022-04-07 | Pfizer Inc. | Cell culture process for producing rsv f protein |
WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
EP4032548A4 (en) * | 2020-08-25 | 2023-01-25 | Beijing Jiaotong University | Combination vaccine against respiratory syncytial virus infections and immune response induction method thereof |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
US11672856B2 (en) * | 2011-03-02 | 2023-06-13 | CureVac SE | Vaccination in newborns and infants |
US11878998B2 (en) | 2016-03-29 | 2024-01-23 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Prefusion RSV F proteins and their use |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
US11975064B2 (en) | 2011-03-02 | 2024-05-07 | CureVac SE | Vaccination with mRNA-coded antigens |
WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101180079B (en) | 2005-04-08 | 2012-07-18 | 惠氏公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
SG188813A1 (en) | 2007-12-24 | 2013-04-30 | Id Biomedical Corp Quebec | Recombinant rsv antigens |
AU2009333484B2 (en) | 2008-12-09 | 2014-12-11 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US8858952B2 (en) * | 2009-02-19 | 2014-10-14 | Mayo Foundation For Medical Education And Research | Methods and materials for generating T cells |
EP4159232A1 (en) | 2011-01-26 | 2023-04-05 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
US9585953B2 (en) * | 2011-03-22 | 2017-03-07 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
CA2849471A1 (en) * | 2011-09-30 | 2013-04-04 | Novavax, Inc. | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
US9241988B2 (en) * | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
RU2518277C2 (en) * | 2012-07-09 | 2014-06-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа" Министерства здравоохранения и социального развития Российской Федерации | Method of treating influenza and influenza-like illnesses complicated with pneumonia |
JP6523955B2 (en) | 2012-08-01 | 2019-06-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | Recombinant modified vaccinia virus Ankara (MVA) RS virus (RSV) vaccine |
SG11201507978XA (en) * | 2013-04-08 | 2015-10-29 | Medimmune Llc | Vaccine composition and method of use |
JP6685903B2 (en) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | RSV pre-fusion F protein that is conformationally stabilized |
CA2925201A1 (en) * | 2013-09-24 | 2015-04-02 | Massachusetts Institute Of Technology | Self-assembled nanoparticle vaccines |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
CN108697790B (en) | 2015-09-03 | 2022-02-18 | 诺瓦瓦克斯股份有限公司 | Vaccine compositions with improved stability and immunogenicity |
CN108300705B (en) * | 2017-01-12 | 2021-10-22 | 厦门大学 | Method for stabilizing respiratory syncytial virus fusion protein |
WO2018175518A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv) |
RU2019130167A (en) | 2017-04-04 | 2021-05-05 | Юниверсити Оф Вашингтон | SELF-ASSEMBLY PROTEIN NANOSTRUCTURES EXPOSING F-PROTEINS OF PARAMIXOVIRUS AND / OR PNEUMOVIRUS AND THEIR APPLICATION |
CN109206491A (en) * | 2017-07-07 | 2019-01-15 | 浙江海隆生物科技有限公司 | Preparation method of porcine pseudorabies virus gD protein, porcine pseudorabies virus subunit vaccine and application |
EP3664836A4 (en) | 2017-08-07 | 2021-05-19 | Calder Biosciences Inc. | Conformationally stabilized rsv pre-fusion f proteins |
EP3758747A1 (en) | 2018-02-28 | 2021-01-06 | University of Washington | Self-asssembling nanostructure vaccines |
AU2019238171A1 (en) | 2018-03-19 | 2020-09-24 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
KR20210013571A (en) | 2018-05-04 | 2021-02-04 | 스파이바이오테크 리미티드 | Vaccine composition |
CN109851678A (en) * | 2019-03-07 | 2019-06-07 | 苏州宇之波生物科技有限公司 | A kind of inferior stable state bovine respiratory syncytial virus of improvement merges DNA molecular and its application of precursor F protein matter and coding |
CN114685627A (en) * | 2020-12-28 | 2022-07-01 | 广州更新生物医药科技有限公司 | rAAV vector vaccine for preventing respiratory syncytial virus |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1652407A (en) | 1924-04-28 | 1927-12-13 | Hastings H Johnson | Wire-measuring device |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
DE3878468T2 (en) | 1987-12-23 | 1993-06-09 | Upjohn Co | CHIMARENE GLYCOPROTEINS, CONTAINING IMMUNOGENIC SEGMENTS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS. |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
ES2108278T3 (en) * | 1992-06-25 | 1997-12-16 | Smithkline Beecham Biolog | COMPOSITION OF VACCINE WITH ADJUSTMENTS. |
CA2151597A1 (en) | 1993-01-08 | 1994-07-21 | Robert L. Garlick | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein |
WO1994021292A1 (en) * | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
PT729473E (en) | 1993-11-17 | 2001-02-28 | Deutsche Om Arzneimittel Gmbh | METHOD FOR PREPARING THE COMPOSITION OF THE PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND THEIR USE |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
FR2718452B1 (en) * | 1994-04-06 | 1996-06-28 | Pf Medicament | Element of immunogen, immunogenic agent, pharmaceutical composition and method of preparation. |
ATE328890T1 (en) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | IMMUNOMODULATORY OLIGONUCLEOTIDES |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
US5620608A (en) | 1995-06-07 | 1997-04-15 | Cobe Laboratories, Inc. | Information entry validation system and method for a dialysis machine |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
KR100550132B1 (en) | 1997-09-19 | 2006-02-08 | 와이어쓰 홀딩스 코포레이션 | Peptides derived from the attachment g protein of respiratory syncytial virus |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
EP1089913A1 (en) | 1998-06-08 | 2001-04-11 | SCA Emballage France | Fast flattening packaging |
CA2337807C (en) | 1998-06-30 | 2012-08-21 | Om Pharma | Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
EP2266604A3 (en) * | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
WO2001046127A1 (en) | 1999-12-22 | 2001-06-28 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
US20040161846A1 (en) | 2000-11-22 | 2004-08-19 | Mason Anthony John | Method of expression and agents identified thereby |
CA2435972C (en) | 2001-01-26 | 2011-09-13 | University Of Lausanne | Matrix attachment regions and methods for use thereof |
WO2002072012A2 (en) | 2001-03-09 | 2002-09-19 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
JP4331944B2 (en) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | New adenine derivatives |
PT1719511E (en) | 2001-11-16 | 2009-03-06 | Coley Pharm Group Inc | N-[4-(4-amino-2-ethyl-1h-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof |
WO2004071459A2 (en) | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
KR101229989B1 (en) | 2003-10-24 | 2013-02-06 | 셀렉시스 에스. 에이. | High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of MAR sequences |
KR100599454B1 (en) * | 2004-04-27 | 2006-07-12 | 재단법인서울대학교산학협력재단 | 3 Novel use of AIM3 acting as a tumor suppressor |
FR2873378A1 (en) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | IMMUNOGENIC COMPLEXES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS |
CA2587084C (en) * | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
TWI457133B (en) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
WO2008114149A2 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
WO2008154456A2 (en) * | 2007-06-06 | 2008-12-18 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
SG188813A1 (en) | 2007-12-24 | 2013-04-30 | Id Biomedical Corp Quebec | Recombinant rsv antigens |
CN102131830A (en) * | 2008-07-18 | 2011-07-20 | 魁北克益得生物医学公司 | Chimeric respiratory syncytial virus polypeptide antigens |
KR20120093811A (en) * | 2009-06-24 | 2012-08-23 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | Vaccine |
AU2010264688A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
CN110506060B (en) * | 2017-03-30 | 2024-05-07 | 昆士兰大学 | Chimeric molecules and uses thereof |
-
2008
- 2008-12-23 SG SG2013014287A patent/SG188813A1/en unknown
- 2008-12-23 LT LTEP08864495.0T patent/LT2222710T/en unknown
- 2008-12-23 EP EP19152924.7A patent/EP3508505A1/en active Pending
- 2008-12-23 EP EP22211934.9A patent/EP4206231A1/en active Pending
- 2008-12-23 EP EP22181399.1A patent/EP4108688A1/en active Pending
- 2008-12-23 DK DK08864495.0T patent/DK2222710T3/en active
- 2008-12-23 CN CN200880127407.3A patent/CN101952321B/en active Active
- 2008-12-23 MX MX2010007107A patent/MX2010007107A/en active IP Right Grant
- 2008-12-23 EP EP23150323.6A patent/EP4219566A3/en active Pending
- 2008-12-23 JP JP2010539977A patent/JP5711972B2/en active Active
- 2008-12-23 RS RS20160792A patent/RS55162B1/en unknown
- 2008-12-23 EA EA201070794A patent/EA021393B1/en not_active IP Right Cessation
- 2008-12-23 WO PCT/CA2008/002277 patent/WO2009079796A1/en active Application Filing
- 2008-12-23 HU HUE08864495A patent/HUE029258T2/en unknown
- 2008-12-23 KR KR1020107016541A patent/KR101617895B1/en active IP Right Grant
- 2008-12-23 EP EP08864495.0A patent/EP2222710B8/en active Active
- 2008-12-23 EP EP16180926.4A patent/EP3109258B1/en not_active Revoked
- 2008-12-23 PL PL08864495T patent/PL2222710T3/en unknown
- 2008-12-23 ES ES08864495.0T patent/ES2597439T3/en active Active
- 2008-12-23 AU AU2008340949A patent/AU2008340949A1/en not_active Abandoned
- 2008-12-23 EP EP22181398.3A patent/EP4108687A1/en active Pending
- 2008-12-23 US US12/810,196 patent/US8563002B2/en active Active
- 2008-12-23 CA CA2710600A patent/CA2710600C/en active Active
- 2008-12-23 ES ES16180926T patent/ES2719406T3/en active Active
- 2008-12-23 SI SI200831685A patent/SI2222710T1/en unknown
- 2008-12-23 PT PT88644950T patent/PT2222710T/en unknown
- 2008-12-23 BR BRPI0821532-4A patent/BRPI0821532A2/en not_active Application Discontinuation
-
2010
- 2010-06-17 ZA ZA2010/04289A patent/ZA201004289B/en unknown
-
2016
- 2016-10-11 CY CY20161101010T patent/CY1118090T1/en unknown
- 2016-10-17 HR HRP20161353TT patent/HRP20161353T1/en unknown
Non-Patent Citations (8)
Cited By (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010006447A1 (en) * | 2008-07-18 | 2010-01-21 | Id Biomedical Corporation Of Quebec | Chimeric respiratory syncytial virus polypeptide antigens |
CN102548578A (en) * | 2009-06-24 | 2012-07-04 | 魁北克益得生物医学公司 | Vaccine |
WO2010149745A1 (en) * | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
WO2010149743A3 (en) * | 2009-06-24 | 2011-03-10 | Id Biomedical Corporation Of Quebec | Vaccine |
US9492531B2 (en) | 2009-06-24 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Recombinant RSV vaccines |
EA023054B1 (en) * | 2009-06-24 | 2016-04-29 | Глэксосмитклайн Байолоджикалз С.А. | Recombinant rsv antigens |
US8889146B2 (en) | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
US20230357371A1 (en) * | 2009-07-15 | 2023-11-09 | Glaxosmithkline Biologicals Sa | Rsv f protein compositions and methods for making same |
CN102639147B (en) * | 2009-07-15 | 2015-11-25 | 诺华股份有限公司 | RSV F protein composition and its manufacture method |
CN102639147A (en) * | 2009-07-15 | 2012-08-15 | 诺华有限公司 | RSV F protein compositions and methods for making same |
EP3178490B1 (en) | 2009-07-15 | 2022-04-20 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
JP2012533558A (en) * | 2009-07-15 | 2012-12-27 | ノバルティス アーゲー | RSVF protein composition and method for making the same |
US20220213177A1 (en) * | 2009-07-15 | 2022-07-07 | Glaxosmithkline Biologicals Sa | Rsv f protein compositions and methods for making same |
EP3988115A3 (en) * | 2009-07-15 | 2022-08-17 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
US20230357370A1 (en) * | 2009-07-15 | 2023-11-09 | Glaxosmithkline Biologicals Sa | Rsv f protein compositions and methods for making same |
US11629181B2 (en) | 2009-07-15 | 2023-04-18 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
US11655284B2 (en) | 2009-07-15 | 2023-05-23 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
US20120164176A1 (en) * | 2009-07-15 | 2012-06-28 | Kurt Swanson | Rsv f protein compositions amd methods for making same |
US11820812B2 (en) | 2009-07-15 | 2023-11-21 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
EP4183412A1 (en) * | 2009-07-15 | 2023-05-24 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
US20240034773A1 (en) * | 2009-07-15 | 2024-02-01 | Glaxosmithkline Biologicals Sa | Rsv f protein compositions and methods for making same |
EP4218799A1 (en) * | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
EP3178490A3 (en) * | 2009-07-15 | 2017-08-30 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
CN105214080A (en) * | 2009-07-15 | 2016-01-06 | 诺华股份有限公司 | RSV F protein compositions and its manufacture method |
US20230357369A1 (en) * | 2009-07-15 | 2023-11-09 | Glaxosmithkline Biologicals Sa | Rsv f protein compositions and methods for making same |
EP4218800A1 (en) * | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
US11261239B2 (en) | 2009-07-15 | 2022-03-01 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and method for making same |
US20230303669A1 (en) * | 2009-07-15 | 2023-09-28 | Glaxosmithkline Biologicals Sa | Rsv f protein compositions and methods for making same |
US20230348574A1 (en) * | 2009-07-15 | 2023-11-02 | Glaxosmithkline Biologicals Sa | Rsv f protein compositions and methods for making same |
WO2011008974A3 (en) * | 2009-07-15 | 2011-04-28 | Novartis Ag | Rsv f protein compositions and methods for making same |
US11827694B2 (en) | 2009-07-15 | 2023-11-28 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
JP2016028088A (en) * | 2009-07-17 | 2016-02-25 | インダストリー アカデミック コーポレーション ファウンデーション, ハルリム ユニバーシティー | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes |
WO2011050168A3 (en) * | 2009-10-21 | 2011-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
US9718862B2 (en) | 2010-10-06 | 2017-08-01 | University Of Washington Through Its Center For Commercialization | Polypeptides and their use in treating and limiting respiratory syncytial virus infection |
WO2012048115A3 (en) * | 2010-10-06 | 2012-06-21 | University Of Washington Through Its Center For Commercialization | Polypeptides and their use in treating and limiting respiratory syncytial virus infection |
AU2011311946B2 (en) * | 2010-10-06 | 2014-10-02 | University Of Washington Through Its Center For Commercialization | Polypeptides and their use in treating and limiting respiratory syncytial virus infection |
CN103282378A (en) * | 2010-10-06 | 2013-09-04 | 华盛顿大学商业中心 | Polypeptides and their use in treating and limiting respiratory syncytial virus infection |
US11672856B2 (en) * | 2011-03-02 | 2023-06-13 | CureVac SE | Vaccination in newborns and infants |
US12036277B2 (en) | 2011-03-02 | 2024-07-16 | CureVac SE | Vaccination with mRNA-coded antigens |
US11975064B2 (en) | 2011-03-02 | 2024-05-07 | CureVac SE | Vaccination with mRNA-coded antigens |
CN103842374A (en) * | 2011-05-13 | 2014-06-04 | 诺华股份有限公司 | Pre-fusion rsv f antigens |
EP3275892A3 (en) * | 2011-05-13 | 2018-03-14 | GlaxoSmithKline Biologicals S.A. | Pre-fusion rsv f antigens |
EP3275892A2 (en) | 2011-05-13 | 2018-01-31 | GlaxoSmithKline Biologicals S.A. | Pre-fusion rsv f antigens |
WO2012158613A1 (en) | 2011-05-13 | 2012-11-22 | Novartis Ag | Pre-fusion rsv f antigens |
WO2013006842A2 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
CN102294027A (en) * | 2011-07-26 | 2011-12-28 | 昆明理工大学 | Respiratory syncytial virus F2 protein subunit vaccine and preparation method thereof |
WO2013031827A1 (en) | 2011-08-29 | 2013-03-07 | 国立大学法人徳島大学 | Rsv mucosal vaccine |
US9701720B2 (en) | 2012-04-05 | 2017-07-11 | University Of Washington Through Its Center For Commercialization | Epitope-scaffold immunogens against respiratory syncytial virus (RSV) |
WO2014079842A1 (en) * | 2012-11-20 | 2014-05-30 | Novartis Ag | Rsv f prefusion trimers |
CN104853769A (en) * | 2012-11-20 | 2015-08-19 | 葛兰素史密丝克莱恩生物有限公司 | Rsv f prefusion trimers |
JP2016519658A (en) * | 2013-03-13 | 2016-07-07 | アメリカ合衆国 | Pre-fusion RSVF proteins and their use |
RU2761631C2 (en) * | 2013-03-13 | 2021-12-13 | Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Rsv proteins in pre-confluence conformation and use thereof |
CN105473604A (en) * | 2013-03-13 | 2016-04-06 | 美国政府(由卫生和人类服务部的部长所代表) | Prefusion RSV F proteins and their use |
US10017543B2 (en) | 2013-03-13 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
JP7043530B2 (en) | 2013-03-13 | 2022-03-29 | アメリカ合衆国 | Pre-fusion RSV F protein and their use |
JP2020089384A (en) * | 2013-03-13 | 2020-06-11 | アメリカ合衆国 | Prefusion rsv f proteins and their use |
WO2014160463A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
US10858400B2 (en) | 2013-03-13 | 2020-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
JP7503588B2 (en) | 2013-03-13 | 2024-06-20 | アメリカ合衆国 | Pre-fusion RSV F proteins and their uses |
CN105473604B (en) * | 2013-03-13 | 2021-01-22 | 美国政府(由卫生和人类服务部的部长所代表) | Pre-fusion RSV F proteins and uses thereof |
US11130785B2 (en) | 2013-03-13 | 2021-09-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
US11981707B2 (en) | 2013-03-13 | 2024-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
EP2970398B1 (en) * | 2013-03-13 | 2024-05-08 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
EP3488864A1 (en) | 2013-04-25 | 2019-05-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
US10899800B2 (en) | 2013-04-25 | 2021-01-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
US10294279B2 (en) | 2013-06-17 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
US20150166610A1 (en) * | 2013-10-14 | 2015-06-18 | Glaxosmithkline Biologicals, S.A. | Recombinant rsv antigens |
US11571472B2 (en) | 2014-06-13 | 2023-02-07 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
WO2016203052A1 (en) * | 2015-06-18 | 2016-12-22 | Vib Vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
AU2016277887B2 (en) * | 2015-06-18 | 2022-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunoglobulin single variable domain antibody against RSV prefusion F protein |
CN108472343A (en) * | 2015-06-18 | 2018-08-31 | 非营利性组织佛兰芒综合大学生物技术研究所 | The immunoglobulin (Ig) list variable domains antibody of F protein before anti-RSV fusions |
US10501528B2 (en) | 2015-06-18 | 2019-12-10 | V18 Vzw | Immunoglobulin single variable domain antibody against RSV prefusion F protein |
US11248039B2 (en) | 2015-06-18 | 2022-02-15 | Vib Vzw | Immunoglobulin single variable domain antibody against RSV prefusion F protein |
CN108472343B (en) * | 2015-06-18 | 2021-12-10 | 非营利性组织佛兰芒综合大学生物技术研究所 | Immunoglobulin single variable domain antibodies against RSV prefusion F protein |
IL256315B1 (en) * | 2015-06-18 | 2023-08-01 | Vib Vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
US11034731B2 (en) | 2015-07-07 | 2021-06-15 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
US11229694B2 (en) | 2015-07-07 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
US10456462B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Preventions B.V. | Vaccine against RSV |
US11998597B2 (en) | 2015-07-07 | 2024-06-04 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
EP3124042A1 (en) * | 2015-07-28 | 2017-02-01 | VIB, vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
US9950058B2 (en) | 2015-12-23 | 2018-04-24 | Pfizer Inc. | RSV F protein mutants |
CN108738312A (en) * | 2015-12-23 | 2018-11-02 | 辉瑞公司 | Rsv f protein mutant |
US10238732B2 (en) | 2015-12-23 | 2019-03-26 | Pfizer Inc. | RSV F protein mutants |
US10821171B2 (en) | 2015-12-23 | 2020-11-03 | Pfizer Inc. | RSV F protein mutants |
US11878998B2 (en) | 2016-03-29 | 2024-01-23 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Prefusion RSV F proteins and their use |
EP3808374A1 (en) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection |
US11155583B2 (en) | 2016-04-05 | 2021-10-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
US11801297B2 (en) | 2016-04-05 | 2023-10-31 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
US11338031B2 (en) | 2016-04-05 | 2022-05-24 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
US10729757B2 (en) | 2016-04-05 | 2020-08-04 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
US11759514B2 (en) | 2016-05-30 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion RSV F proteins |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US10953087B2 (en) | 2016-05-30 | 2021-03-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion RSV F proteins |
WO2018114892A1 (en) | 2016-12-20 | 2018-06-28 | Glaxosmithkline Biologicals S.A. | Novel methods for inducing an immune response |
WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
WO2018219521A1 (en) | 2017-05-30 | 2018-12-06 | Glaxosmithkline Biologicals S.A. | Methods for manufacturing an adjuvant |
US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
WO2019106192A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
WO2020099383A1 (en) | 2018-11-13 | 2020-05-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
EP4032548A4 (en) * | 2020-08-25 | 2023-01-25 | Beijing Jiaotong University | Combination vaccine against respiratory syncytial virus infections and immune response induction method thereof |
WO2022070129A1 (en) | 2020-10-02 | 2022-04-07 | Pfizer Inc. | Cell culture process for producing rsv f protein |
WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
WO2023066872A1 (en) | 2021-10-19 | 2023-04-27 | Glaxosmithkline Biologicals Sa | Adjuvant composition comprising sting agonists |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014203636C1 (en) | Recombinant RSV antigens | |
US8563002B2 (en) | Recombinant RSV antigens | |
US20100203071A1 (en) | Chimeric antigens | |
EP2445527A2 (en) | Vaccine | |
US20160122398A1 (en) | Recombinant rsv antigens | |
EP2324062A1 (en) | Chimeric respiratory syncytial virus polypeptide antigens | |
AU2013201836B2 (en) | Recombinant RSV antigens | |
BAUDOUX et al. | Patent 2710600 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880127407.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08864495 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008340949 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2008864495 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008864495 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2710600 Country of ref document: CA Ref document number: 2010539977 Country of ref document: JP Ref document number: 12810196 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/007107 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008340949 Country of ref document: AU Date of ref document: 20081223 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5294/DELNP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20107016541 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201070794 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: PI0821532 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100624 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2016/0792 Country of ref document: RS |